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ABSTRACT: 
Introduction and Objectives: 
Respiratory Syncytial Virus (RSV) is the commonest cause of bronchiolitis in 
infants. This negative strand RNA virus is known to infect and replicate in the 
airway epithelium.  RSV infection induces elevated levels of reactive oxidative 
species and subsequent oxidative stress injury in the lungs. Nrf2, a transcription 
factor that regulates antioxidant protein expression, has an important role in 
preventing pulmonary oxidative damage. Sulforaphane is a potent, naturally 
occurring inducer of NRF2 found in vegetables such as broccoli. In this study we 
sought to determine whether Nrf2 induction by sulforaphane might reduce RSV 
replication in airway epithelial cells. We also selected six proteins including MAVS, 
DDX21, RPS10, prohibitin, annexin A1, HMGB1 from proteomics defining changes 
in their level of ubiquitination following RSV infection. Our aim was to determine 
which proteins change their level of polyubiquitination following the infection. This 
could help identify new biochemical pathways involved in the host defence or viral 
replication and new targets for potential therapeutic intervention. 
Method: 
BEAS2B cells were infected with RSV at MOI of 1 following pre-treatment with 
sulforaphane. Samples were harvested at time points 24 and 48 hours and 
analysed by Western Blotting for NrF2 and RSV. In addition, RT-qPCR was carried 
out for RSV quantification using an RSV N primer. A549 cells were infected with 
various concentrations of RSV (1:4-4:1). Samples were harvested at time point of 4 
and 24 hours and analysed by Western Blotting using antibodies to ubiquitin and 
target proteins selected from ubiquitination proteomics data . Immunoprecipitation 
was used to confirm ubiquitination of these proteins and immunohistology to 
confirm their cellular localisation. Proteasome activity was inhibited using MG132 a 
specific, potent, reversible, and cell-permeable proteasome inhibitor.  
Results: 
Sulforaphane induced Nrf2 production in BEAS2Bs in a dose dependent manner. 
Results do not show that RSV replication is reduced in airway epithelial cells pre-
treated with Sulforaphane. However, preliminary data suggests that virus might 
have degrading effect on Nrf2. Western blots demonstrate changes in expression 
of target proteins and their ubiquitination following RSV infection and proteasome 
inhibition. Breakdown products of DDX21 and MAVS were detected in RSV 
infected samples.  
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Conclusions: 
RSV infection changes expression of target proteins in A549 cells and might have 
influence on their ubiquitination, however, most probably it does not affect 
expression of Sulforaphane induced Nrf2. DDX21 and Nrf2 are likely to be 
degraded by the virus but results have to be confirmed in further experiments. 
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Abbreviations: 
%- Percentage 
°C- Degree Celsius 
µl- Microlitre 
 AOE- Antioxidant enzyme 
BCA- Bicinchoninic acid assay 
BSA- Bovine Serum Albumin 
CCA - Chimpanzee Coryza Agent 
COPD- chronic obstructive pulmonary disease  
CO2- Carbon dioxide 
DAMP - Damage-Associated molecular Patterns 
DMEM- Dulbecco’s Modified Eagles Medium DMEM 
DNA - Deoxyribonucleic Acid 
DTT- Dithiothreitol  
DUBs- De-ubiquitinising enzymes  
EDTA- Ethylenediaminetetraacetic acid 
FCS- Foetal Calf Serum 
hMPV- Human Metapneumovirus  
IFN – Interferon 
KSHV- Kaposi's sarcoma-associated herpesvirus  
kDa- Kilodalton 
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L- Litre 
L protein- Large Protein 
LRT - Lower Respiratory Tract 
mL- Mililitre 
mM- Milimolar 
M protein- Matrix protein 
Maf- Musculoaponeurotic fibrosarcoma  
MVB- Multivesicular body pathway  
MOI- Multiplicity of Infection 
MW- Molecular Weight  
N protein- Nucleocapsid protein 
NF-ҡB - Nuclear Factor Kapper B NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) 
NK - Natural Killer Cells 
NRF2- Nuclear factor (erythroid-derived 2)-like 2 
NS1- Non Structured Protein 1 
NS2- Non Structured Protein 2 
ORF1- Open reading frame 
PAMP- Pathogen associated molecular patterns  
PBS- Phosphate Bovine Serum  
PCR - Polymerase Chain Reaction 
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PFU- Plaque Forming Units 
P protein – Phosphor protein 
PVDF- Polyvinylidene fluoride 
PreF- Pre-fusion form  
PostF- Post- fusion form 
qPCR- quantitative PCR   
RNP- Ribonucleoprotein complex 
RNA - Ribonucleic Acid 
ROS- Reactive oxygen species  
RSV - Respiratory Syncytial Virus 
SDS- Sodium dodecyl sulphate 
SH- small hydrophobic protein 
SOD- Superoxide dismutase 
TBS-T- Tris-Buffered Saline and Tween 20 
TLR- Toll- like receptors  
UBL- Ubiquitin like domain  
UBA- Ubiquitin associated domains  
URT- Upper Respiratory Tract 
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1. Introduction 
1.1. Respiratory Syncytial Virus 
Respiratory Syncytial Virus (RSV) is one of the leading causes of 
respiratory disease in infants and is a major threat for child health 
worldwide, regardless of socioeconomic status. It also contributes to 
an increase in mortality and hospitalisation rates in the elderly and 
immunosupressed. 1 The virus causes bronchiolitis, lower respiratory 
conditions characterised by dry coryza, cough and fever.2 In addition 
to the consequences of its acute symptoms, it has been linked to 
asthma and recurrent wheeze in later life. All these aspects make the 
disease a great burden on both society and the NHS.2 
1.1.1. Virology- overview of the virus structure 
RSV is a double stranded, enveloped RNA virus from the 
Paramyxoviridae family.  Although mainly veterinary viruses, there 
are two human viruses in this family- RSV and metapneumovirus.3 Its 
genome consists of 15,222 nucleotides and encodes for 11 proteins. 
Nine of those proteins are structured virion components and 2 are 
non- structured proteins 1 and 2 (NS1, NS2) responsible for 
opposing the host innate immune response4. Two proteins located on 
the surface of the virus- proteins F and G play crucial roles in viral 
infection. Protein G is responsible for attaching to the host cell by 
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targeting ciliated airway epithelium and protein F for fusing viral and 
cellular membranes and allowing entry into the cell. Protein F also 
gives the virus its name as it stimulates production of syncytia 
enabling direct cell to cell spread.5 Thanks to antigenic determinants 
of these two proteins, the host’s body produces neutralising 
antibodies.6 Protein F exists in two forms, pre- and post-fusion. The 
pre-fusion form (PreF) is the main target for the development of 
antiviral drugs due to its superiority in inducing neutralising 
antibodies in comparison to its post-fusion form (PostF).7  Proteins G 
and F are two out of three integral membrane proteins inserted in a 
lipid envelope surrounding the virus. The third protein is the small 
hydrophobic (SH) protein but its role is currently unknown.8 The RSV 
genome is protected by helical nucleocapsid which also provides a 
replication template.9 A mature RSV particle consists of 
ribonucleoprotein (RNP) complex created by viral RNA (vRNA), the 
nucleocapsid (N) protein, the phosphor (P) protein and the large (L) 
protein interacting with one another. The P protein is an essential 
component of polymerase complex providing clearance and chain 
elongation during transcription. The L protein is responsible for RNA 
synthesis stimulation, encoding RNA polymerase, as well as RNA 
transcription and replication.10 These proteins are essential for 
minimal functional polymerase activity; however, matrix proteins also 
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contribute to its efficiency. These proteins are called M2-1, M2-2 and 
M and all are required for transcription. M2-1 is a transcription factor 
and M2-2 is a regulatory factor responsible for balance between 
replication and transcription. M2 mRNA consists of two open reading 
frames (ORF1 and ORF2) which overlap. ORF1 promotes chain 
elongation during transcription and optimizes mRNA production. 
ORF2 plays a role in accumulation of genomic and antigenomic 
RNA11. M protein, located on the viral envelope, is a matrix protein 
which enables interaction of plasma membrane and 
ribonucleoprotein complexes (RNPs) during virion synthesis. As 
mentioned earlier, NS1 and NS2, which are not part of the mature 
virion structure, are secreted proteins responsible for antagonising 
the interferon system.  They increase the severity of disease by 
blocking production of type I interferon (IFN) and causing rapid 
replication of the virus. NS1 has a greater IFN inhibiting effect in 
comparison to NS2 but both work synergistically.12 A schematic 
illustration of RSV particle is presented in Figure 1.1. 
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Figure 1.1. Schematic illustration of RSV particle. 
 
A single particle of RSV showing its envelope and negative single RNA strand. 3 surface proteins 
(G,F,SH) are shown outside the virus particle and protein M (matrix), L (polymerase), N (nucleocapsid) 
and P (phosphoprotein), as well as two transcription and termination factors M2-1 and M2-2 inside the 
cell. Non-structural proteins NS1 and NS2 are not shown in the picture.(4)  
 
1.1.2. History and discovery of RSV 
RSV was first described in 1957 as “Chimpanzee Coryza Agent” by 
Blount et al, following an outbreak of disease in research purpose 
kept group of Chimpanzees.13 Symptoms of bronchiolitis however, 
had been described earlier in 1857 by Eberle but at that time, the 
cause of the disease was unknown.14 It was the lack of bacteria 
detected in the infected sample almost 100 years later (in 1955), 
which made Adams think that the outbreaks of respiratory disease in 
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infants characterised by cyanosis, cough and dyspnoea might have a 
viral cause.15,16 In 1957, Chanock et al discovered that “Chimpanzee 
Coryza Agent” cannot be structurally distinguished from the virus 
causing bronchiolitis symptoms in infants.17 The name RSV came 
from ‘syncytia’, or pseudo large cells, which were observed in 
infected human epithelial cells. The same group of scientists 
identified the main characteristics of RSV, including its link to 
bronchiolitis and pneumonia, its seasonability in winter months and 
its propensity to infect young infants.18 
1.1.3. Epidemiology 
RSV infections are very common. Every winter the virus causes 
outbreaks of bronchiolitis in children under the age of 1. The majority 
of cases in the Northern Hemisphere are recorded between 
November and April19 (Figure 1.2.). Almost all children will have had 
a RSV infection before the age of 5, with 70% of children being 
exposed to the virus in the first 12 months of life.20 Incidence peaks 
during 3rd and 4th month of life.21 There are two major genetic 
subgroups, A and B which co-circulate, and their predominance 
varies by year and geographic location.22 Worldwide, RSV is 
estimated to cause over 30 million lower respiratory tract infections 
each year which contribute to more than 3 million hospitalisations. 
This makes it the most common cause of hospital admissions in 
23 
 
children under 5 years of age.23 Overall, 2-3% of children under 1 
who are infected with RSV get admitted to hospital.24 (Figure 1.3. 
presents hospital admission rates from bronchiolitis in years 2010-
2011 in the UK.) In developing countries, bronchiolitis has been 
reported as the second commonest cause of death during the first 12 
months of life after malaria.25 In the United Kingdom, mortality rates 
from bronchiolitis have decreased from 21.47 in 1979 to 1.82 per 
100,00 live-births in 2000.26 Re-infection rates of the virus are also 
vey high, with 74-83% in the 2nd year and 46-65% in the 3rd year of 
life reported in literature.27 This data shows that human immunity 
provides insufficient protection from the virus and highlights the 
importance of treatment development. 
Clinical research data from both the USA and Britain report high 
rates of Intensive Care Unit admissions and need for mechanical 
ventilation in children with bronchiolitis.28 A study conducted in 5 
London Paediatric Intensive Care Units showed that the average 
length of assisted ventilation needed by a child with bronchiolitis was 
4.4 days and the average length of hospital stay was 15.9 days.29 
RSV infection is an enormous burden not only on a patient’s health 
but also on the economy. The predicted annual cost of treating RSV 
infection is 600-750 million USD.30 
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Figure 1.2. Graph presenting number of RSV isolates per week, 
recorded in Alder Hey Hospital shows seasonality of the disease. 
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Figure 1.3.  Hospital admission rates for bronchiolitis in the UK in 
2010/2011. 
 
Images showing differences in hospital admission rates for bronchiolitis in the UK in 2010-2011 in 
Primary Care Trusts. The values are per 100,000 population aged <2 years. Number of admissions in 
Liverpool is one of the highest in the country. Data from National Child and Maternal Health Intelligence 
Network Website (www.chimat.org.uk). 
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1.1.4. Clinical features and presentation 
Presentation of bronchiolitis varies depending on the age of the 
patient and the severity of symptoms. Mild RSV infection usually 
results in mild upper respiratory tract (URT) symptoms and does not 
require medical intervention. However, more severe disease causes 
significant lower respiratory tract (LRT) symptoms which manifest as 
bronchiolitis or pneumonia and often require hospital admission. 
Children with LRT symptoms usually present with cough (98%), fever 
(75%), rhinorrhoea, wheezing (65-78%), increased work of breathing 
(73-95%) and sometimes hypoxia.31 Symptoms of more severe 
disease include: grunting, nasal flaring, subcostal and intercostal 
recession. Older children usually present with URT symptoms like 
cough, coryza, rhinorrhoea and conjunctivitis.32 Predicting severity 
based on symptoms might be misleading because children can 
appear disproportionally ill/well.33 However, factors associated with 
more severe disease in full term children include age <60 days, male 
sex, increased respiratory rate, increased work of breathing, lower 
socioeconomic status or poor oral intake.34 
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1.1.5. Risk factors and prognosis 
Even though all infants are susceptible to RSV infection and 
bronchiolitis, the following risk factors make the chance of morbidity 
much higher: pre-existing chronic lung disease (eg 
bronchopulmonary dysplasia), current weight of less than 5 kg, 
existing cyanotic heart disease, immune compromise (eg severe 
combined immunodeficiency), in utero exposure to tobacco smoke, 
low socioeconomic status, neuromuscular disease and premature 
birth- before 35 weeks of gestation. Atopy or family history of atopy 
have also been reported to be associated with more severe forms of 
disease.35  
The majority of patients with RSV infection recover uneventfully and 
significant disease does not recur. However, 40% of children 
hospitalised with bronchiolitis have significantly more wheezy 
episodes during the first 5 years of life than age matched controls, 
with 10% continuing to have wheezy episodes past the age of 5.36 A 
study by Blanken et al, in which healthy pre term infants were 
prophylactically treated with palivizumab, showed decrease in 
number of wheezy days during the first year of life in comparison to 
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control group and proved that RSV infection plays significant role in 
the pathogenesis of recurrent wheeze during the first year of life.37 
1.1.6. Management and prevention 
Despite the importance of the disease, a lack of in-depth knowledge 
about the pathogenesis has resulted in inadequate treatment and 
vaccination options available. In groups of ex-preterm neonates at 
the highest risk of severe disease, palivizumab (a monoclonal 
antibody) is administered. However, it is only effective as prophylaxis 
not as a therapeutic. Use of the antibody has not been extended to 
the general population. The process of vaccine development has 
been significantly prolonged due to safety concerns, biological 
barriers and practical problems. Extensive research in infected 
people and animal models has not yet led to commercially available 
effective antivirals or vaccines, with the exception of palivizumab for 
immunoprophylaxis in selected high-risk children. Due to the lack of 
knowledge about the virus’ intermediate host or animal reservoir, it is 
argued that if the vaccine was administered before the first RSV 
infection, virus ecology could drastically change and stop the ability 
of RSV to continually re-infect humans.38  
Currently in the majority of cases, RSV bronchiolitis treatment is 
supportive, consisting of close monitoring of the clinical symptoms 
and if necessary IV fluids and oxygen.39 As a result of overcautious 
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attitudes and a lack of set treatment protocol, patients often undergo 
unnecessary treatment with antibiotics, steroids or inhaled 
bronchodilators despite a lack of evidence-based data about their 
effectiveness. Bronchodilators (eg nebulised salbutamol) have been 
reported to cause modest short term improvement, however, a 
definitive benefit with acute symptoms has not been demonstrated.40 
Anti-inflammatory medication, such as systemic and nebulised 
corticosteroids, have demonstrated no benefits as bronchiolitis 
treatment.41 
1.2. Pathogenesis 
RSV replicates in the nasopharynx, where epithelial cells are the 
primary line of defence, causing URT symptoms. 
1.2.1. Viral infection and cytotoxicity 
After 2-8 days of incubation, the virus infiltrates the small bronchiolar 
epithelium causing LRT symptoms. Viral shedding usually lasts 3-8 
days but in some cases can extend up to four weeks.42 In cases 
which progress to LRT, pathological changes develop including 
oedema, enhanced mucus production and ultimately necrosis and 
regeneration of the airway lining. These changes result in small 
airway obstruction, air trapping and increased airway resistance.43 In 
turn this can lead to hypoxia and respiratory failure.44 
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Due to RSV pathogenesis being not fully understood, information 
available in the literature is not abundant and remains controversial. 
The impact of the host response is reduced because the virus targets 
superficial epithelial cells. Lung injury is exacerbated both by the 
direct cytotoxic effect of the virus and inflammatory responses 
elicited against the virus.45 Some studies show that it is only after 
epithelial cells have released inflammatory mediators that apoptosis 
occurs.46 RSV has been reported to cause ciliary damage not long 
after infection, as well as delayed cell death, even weeks after 
infection.47 Numerous studies suggest that damage caused by RSV 
is to a great extent immune response mediated.48 Continuous 
stimulation of the immune system caused by persistent viral infection, 
may cause chronic inflammation or changes in the expression of 
immunoregulatory molecules, which may explain why the clinical 
symptoms persist long after the acute viral infection has resolved.49 
 
 
1.2.2. Immune response to RSV infection 
The human immune system can be split into two parts- innate and 
adaptive immunity. Both of those components work synergistically to 
recognize and remove unwanted matter from the organism and 
minimise the damage during the immune response.50 The first line 
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defence is the innate system, which is always present and helps in 
the induction of the adaptive system. RSV infects and replicates in 
airway epithelial cells. These host cells express toll- like receptors 
(TLR), sensors detecting pathogen specific structural motifs. They 
recognize virus pathogen associated molecular patterns (PAMP) and 
initiate expression of cytokines, soluble protein mediators which 
regulate the immune response. 51 One of the receptors (TLR-4), 
binds to the RSV F protein (Section 1.1.1.) and together with CD14 
starts NF-κB  (nuclear factor kappa-light-chain-enhancer of activated 
B cells) mediated cytokine production.52 The cytokines produced 
during TLR-4 engagement initiate neutrophil and natural killer (NK) 
cell migration into the lungs, where they may be themselves further 
stimulated by virus or surrounding cytokines.53 Notably neutrophils, 
although apparently needed to control RSV infection, have also been 
suggested to damage airway tissue.54 
Adaptive immunity which includes T cell-mediated immunity and 
antibody production by B cells is characterised by immunological 
memory and tolerance to the body’s own tissues.55 Studies 
conducted on animal models have found that RSV infection 
considerably changes host innate immunity, which in turn leads to 
impairment of an efficient adaptive immunity reaction to infection.56 
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The two systems are highly integrated and comprised of both 
specialised cells and humoral factors.57 
 One example of cell’s response to viral infection is the interferon 
(IFN) pathway. Interferons are a group of cytokines of a pleiotropic 
type named after their property of ‘interfering’ with viral replication.58 
Studies on murine models stress the importance of reduced IFN 
expression in cases with increased RSV spread.59 IFNs can be split 
into two groups. Type I can be expressed by the majority of cells and 
consists of many IFN- α forms and one IFN-β form. During infection 
with virus, this type of IFN is expressed rapidly in response to viral 
RNA or DNA recognition. Cells at or around the site of infection are 
activated via IFN receptors on the cell surface leading to inhibition of 
viral replication through production of endonuclease which destroys 
viral DNA/RNA and inhibits translation. Type I IFN also up regulates 
major histocompatibility complex (MHC) class I production, which 
increases the chance of cytotoxic lymphocytes identifying an infected 
cell and increases NK cell activity which up-regulates the production 
of proteins such as inflammatory chemokines.60 A study by Spann et 
al suggests that expression of IFNs is a very early host reaction to 
RSV, and that a major method of RSV inhibiting innate immunity is 
by inhibiting IFN secretion.61 
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Type II IFN group consists only of IFN-γ and it is expressed by 
macrophages, Natural Killer T and Natural Killer cells. IFN-γ is 
recognized as a part of immune response but the exact part it plays 
is unknown.62 
Another molecule of importance in viral infection is Nrf2, a 
transcription factor which has been recognized as an essential 
regulator of cellular oxidative stress response caused by viral 
infection. Its role is described in greater detail in Section 1.3.1. 
1.3. NRF2 
Nrf2 also known as NF-E2-related factor-2, is a transcription factor, 
profusely expressed in macrophages.63 It has been recently 
recognised as one of the main cellular defence mechanisms against 
environmental toxins and carcinogens. Its main role is to stimulate 
oxidant response and initiate transcription of genes, which protect the 
organism from oxidative stress effects and results in the re-
establishment of homeostasis.64 
1.3.1. Molecule overview  
Emerging studies suggest that Nrf2 has a major part in the 
pathogenesis of various types of cancer, chronic lung disease and 
host defenses against viral infection of the respiratory system.65 In a 
healthy cell, Nrf2 is suppressed by Keap1 protein (Kelch-like 
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erythroid cell-derived protein with CNC homology ECH-associated 
protein 1)66, dependent on another protein- Cullin 3 (Cul3). This 
Keap1-Nrf2 pathway is the main method in which cells regulate 
protective responses to internal and external stresses resulting from 
reactive oxygen species (ROS).67 Keap1 is a substrate adaptor which 
keeps Nrf2 in the cytoplasm and helps Cul3 ubiquitinate Nrf2 when 
the cell is in redox homeostasis. Ubiquitinated Nrf2 is transported to 
proteasome for Cul3-ubiquitin mediated degradation68 (Figure1.4.).  
Figure 1.4. Degradation of Nrf2 in healthy cells. 
 
In a non-infected cell Nrf2 is kept in the cytoplasm by Keap1 and Cullin3. Keap1, a substrate adaptor, 
helps Cull3 degrade Nrf2 by ubiquitination. Nrf2 is marked with ubiquitin and degraded and recycled in 
the proteasome. This process happens very quickly as Nrf2 half life is only 20 minutes.69 
 
Keap1 has multiple cysteine residues which can be regulated in vitro 
by various oxidants. If a cell undergoes oxidative stress, Nrf2 is 
released from the complex by a change in Keap1 cysteine disulfide 
bonds, undergoes phosphorylation and is translocated to the 
nucleus.70 Three of the cysteine residues, C151, C273 and C288 
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have been reported to alter the structure of Keap1 which results in 
nuclear translocation of Nrf2 and target gene expression.71 Even 
though the precise method of cysteine modification in Keap1, which 
activates Nrf2, is not fully understood, there are two proposed 
models explaining this process. The first one is the “hinge and latch” 
model which suggests that Keap1 modification in thiol residues of 
Keap1 blocks the interaction with Nrf2. This results in Nrf2 lysine 
residue misalignment and inability to polyubiquitnate the transcription 
factor. In the second model on the other hand, thiol modification 
results in Cul3 dissociating from Keap1. In both models, modified by 
inducer and bound to Nrf2 Keap1, is inactive. Newly formed Nrf2 
proteins bypass Keap1 and are translocated into the nucleus where 
together with the small Maf proteins, attach themselves to antioxidant 
response element (ARE) and induce expression of Nrf2 target 
genes72 (Figure 1.5.). 
Agents which regulate Keap1-Nrf2 pathway have been of recent 
interest as therapeutic targets for treatment of oxidative stress 
results. 
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Figure 1.5. Disruption of Keap1- Cul3 ubiquitination system in 
infected cells. 
 
Under oxidative stress, the Keap1-Cul3 ubiqutiination system is disrupted. Nrf2 is released from the 
complex by a change in Keap1 cysteine disulfide bonds and translocated to nucleus. Nrf2 is not 
degraded anymore so it binds to a DNA promoter (Maf) in the nucleus and starts transcription of 
antioxidative genes and their proteins.73 
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1.3.2. Target genes 
The protective mechanism of Nrf2 relies on inducing transcription of 
genes which reduce lung injury caused by oxidative stress. A number 
of genes have already been identified but modern technical 
advances have allowed definition of the transcriptional changes 
induced following Nrf2 induction and  provided further  data about 
direct target genes of Nrf2.74 These genes include: 1. Intracellular 
redox-balancing proteins involved in heme and iron metabolism like 
heme oxygenase-1 (HMOX-1) or  glutathione metabolism- glutamate 
cysteine ligase (GCL). 2. Phase II detoxifying enzymes involved in 
drug metabolism like NAD(P)H quinine oxidoreductase-1 (NQO1) 3. 
Transporters (multidrug resistance-associated proteins, MRPs)75 as 
well as transcription factors, metabolic enzymes and antioxidants76. 
Antioxidant response element (ARE) is necessary for Nrf2 binding 
and gene induction and is a specific DNA sequence located on the 
promoter region of Nrf2 target genes. There are many other Nrf2 
downstream genes which are responsible for other cellular processes 
like cell growth and death, inflammatory response, DNA repair and 
ubiquitin- mediated degradation pathway (Section 1.4.3.).77 Nrf2 
downstream genes are heterogenous in nature, which shows the 
importance of their role in detoxification and survival of cells.78 
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1.3.3. Existing evidence of Nrf2 importance 
Over 200 diseases have been reported to cause oxidative stress in 
cells.79 These include Chronic Obstructive Pulmonary Disease, 
asthma, various types of cancer and neurological diseases including 
multiple sclerosis and Alzheimer’s, cardiovascular and metabolic 
disorders such as diabetes, vision disorders and ageing. In this 
project the focus is on infection with RSV, however, other viruses 
such as Humman Immunodeficiency Virus (HIV), Hepatitis B (HepB) 
and C (HepC) have been reported to stimulate reactive oxygen 
species (ROS) both in vitro and in vivo.80 One of the characteristics of 
Nrf2, which demonstrates its importance, is its polymorphism. 
Various studies report its numerous gene variants and haplotypes 
appearing in different diseases. For example Arisawa et al described  
an Nrf2 gene promoter polymorphism and its relationship with 
Helicobacter infection in chronic gastritis.81 Another paper by 
Cordova et al describes a particular genotype of Nrf2 (-653G/A) 
which plays an important role in nephritis during childhood-onset 
systemic lupus erythematosis (SLE).82 Different haplotypes in the 
promoter region of Nrf2 have also been found in COPD by Hua et 
al.83 Most important for this MPhil project, however, is the study by 
Cho et al stating that Nrf2 has antiviral properties in a murine model 
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of RSV. In their experiments, mice deficient in Nrf2 suffered from 
much more severe RSV induced disease in comparison to control 
mice. The severity was assessed on the basis of higher viral titers, 
augmented inflammation, enhanced mucus production and epithelial 
injury. It stresses the importance of Nrf2 mediated cellular antioxidant 
mechanism in pulmonary anti-RSV activity.84  
The versatile role of NRF-2 in protecting different systems in the 
human body is shown in Figure 1.6. 
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Figure 1.6. Nrf2 as a multi organ protector in the body.85 
 
Diagram presents various organs and cell types protected by Nrf2 which increases ARE-driven 
detoxification and antioxidant genes transcription. Nrf2 is a crucial component of antioxidant pathways 
in respiratory and nervous system, skin, liver, gastrointestinal system, kidney, spleen, erythrocytes and 
retinal epithelia. 
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1.3.4. Nrf2- ARE pathway 
In a normal cell, a part of aerobic metabolism is the production of 
reactive oxygen species (ROS) via respiration and oxidation to create 
energy. When the level of ROS is elevated (for example as a 
consequence of infection or exposure to toxins, environmental 
pollutant or radiation) harmful changes caused by oxidation occur in 
a cell. Respiratory viruses such as RSV, human metapneumovirus 
(hMPV) or influenza, stimulate production of ROS and decrease 
antioxidant enzyme (AOE) efficiency resulting in oxidative injury due 
to unbalance oxidative-antioxidants status. Nrf2 controls production 
of AOE by binding to antioxidant responsive element (ARE) in AOE 
gene promoters. When the cell is exposed to majority of pro-oxidant 
stimuli, Nrf2 is induced and AOE expression upregulated. During viral 
infections however, AOE expression is inhibited, Nrf2 nuclear 
localisation is reduced and transcription of ARE-dependent genes 
inhibited. For that reason, agents inducing Nrf2 or antioxidant 
mimetics are a possible therapeutic means of treating harmful effects 
of respiratory viral infections.86 Nrf2-Are pathway has been examined 
in numerous studies, in which pulmonary disorders resulted from 
various antioxidant and inflammatory agents. These experiments 
were conducted on mice and showed that animals deficient in Nrf2, 
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in which the ARE-driven antioxidant expression is suppressed, have 
exacerbated lung inflammation and injury in comparison to control 
animals.87 
It has been previously reported that Nrf2 expression is significantly 
reduced in RSV infection which might be a potential mechanism for 
reducing gene expression of AOE. This can be caused by a range of 
factors like reduced transcription or increased mRNA degradation. 88 
1.3.5. Nrf2 as a clinical drug target 
A large number of studies proving how important Nrf2 is in protecting 
the human body against an array of diseases, lead to a huge interest 
in developing Nrf2 based therapies. Since pathogenesis of viral-
associated lung disease including RSV infection is so strongly related 
to oxidative stress, agents with potential to regulate antioxidative 
pathways seem like a rational therapeutic approach to these 
diseases.89 Antioxidants are known to quench free radicals, which 
decreases oxidative damage and enables cells to function normally. 
Komaravelli et al. tested two therapeutic approaches: Superoxide 
dismutase (SOD) mimetics, which decrease oxidative damage by 
interacting with free radicals and Nrf2 inducers which regulate AOE 
gene expression. A number of compounds, of both synthetic and 
natural origins, have been reported as stimulating Nrf2-ARE 
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influenced transcription. They can be broadly divided into two groups: 
Triterpenoids and isothiocyanates.90 Triterpenoids originate from 
oleanolic acid, which itself has been reported to have antioxidative 
properties.91 Isothiocyanates include Sulforaphane, mainly found in 
cruciferous vegetables like broccoli. It has been reported to change a 
number of cysteine residues in Keap1 by releasing Nrf2, which 
results in elevated nuclear localisation of Nrf2 and ARE 
transcription.92 Kesic et al. showed increased levels of Nrf2 in 
epithelial cells treated with Sulforaphane before Influenza infection, 
which contributed to reduction in viral replication. 93 In a different 
study, mice treated with sulforaphane were shown to have reduced 
numbers of neutrophils and eosinophils after infection.94 These 
findings imply that this compound has a big potential for regulating 
viral induced oxidative disease process.95  
Nrf2 is known to be differentially ubiquitinated and the ubiquitinated 
form rapidly degraded by the proteasome to inhibit Nrf2 activity. 
Differential regulation of protein activity in a manner similar to Nrf2 
occurs for many proteins but has never been studied in relation to 
viral infection. This type of modification could lead to both activation 
or inactivation of a protein and also translocation and movement of it 
in a cell.96 In this thesis I first examined differential ubiquitination of 
Nrf2 in response to viral infection and then expanded this work to a 
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number of candidate genes identified by proteomics. These 
molecules are introduced at the beginning of Chapter 4.  
1.4. Ubiquitin 
Ubiquitin (Ub) is a highly conserved protein, consisting of 76 amino 
acids. In a cell, Ub is linked to target proteins by covalent bonds, in a 
process called ubiquitination. Its name comes from its ubiquitous 
nature, as it is found in all eukaryotic organisms. 97 Ubiquitination is 
one of the best described post-translational alterations which controls 
protein expression and function.98 
1.4.1. Ubiquitination process 
The process is based on an enzymatic cascade. The first enzyme in 
the cascade is E1 which hydrolyses ATP, activates ubiquitin and 
transfers it to a cysteine of the second enzyme E2- a ub-conjugating 
enzyme. The final enzyme is E3 which creates an isopeptide bond 
between ubiquitin’s carboxyl terminus and target protein.99 E2 and E3 
most often determine substrate selection. So far there are only a few 
E1 enzymes known in mammals, about 30 E2 enzymes and 
hundreds of E3 enzymes. The final product of the first stage of 
ubiquitination is the mono- ubiquitinated protein. Every ubiquitin 
molecule has a specific lysine which can be used to initiate 
attachment of consecutive ubiquitin molecules. The effect of this 
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process is a target protein with polyubiquitinated chain. Damaged or 
misfolded proteins are marked by ubiquitin and are transported to 
proteasome and destroyed in the ub-proteasome system (UPS).100 
Other ubiquitinated proteins (eg. transmembrane proteins) are 
transported to a lysosyme via the multivesicular body pathway 
(MVB).101 UPS protein degradation is a key process in DNA damage 
repair, cell cycle regulation, cell development and immune system 
function.102 It has also been reported that ubiquitin takes part in 
protein function and protein interaction with the help of specific 
hydrolazes. These structures have similar function as kinases and 
phosphatases in the phosphorylation process. The whole process is 
very versatile and can be reversed, influencing various properties of 
proteins, not only their stability.103 
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Figure 1.7. Schematic picture of ubiquitination process. 
 
Schematic diagram of the ubiquitination system. Created by Roger B. Dodd. The first enzyme in the  
cascade is E1 which hydrolyses ATP, activates ubiquitin and transfers it to a cysteine of the second 
enzyme E2. E2 is a ub-conjugating enzyme. The final enzyme is E3 which creates an isopeptide bond 
between ubiquitin’s carboxyl terminus and target protein, 104 
 
1.4.2. Molecule overview  and interaction with viruses 
The genes encoding for this protein are grouped in tandem repeats, 
due to high demands for transcription of this protein in all cellular 
processes. Ubiquitin is a very versatile protein thanks to its seven 
lysines and extra residues, used by Ub ligases to create different 
kinds of Ubiquitin chains on target proteins. This results in 
interactions with different downstream factors.105 An example is the 
well known K-58 based linkage which results in proteasome-
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mediated protein degradation or K-63 based control of protein 
endocytosis, as well as enzyme activity.106 
Being obligated intracellular parasites, viruses have to overcome 
host cellular machineries at every stage of their life cycle including 
entry into the cell, replication and genome transcription, protein 
synthesis etc. up until release from the infected cell. Knowing how 
important ubiquitination is in those cellular processes, it is expected 
that ubiquitin and proteins affected by it, must play a part in viral life 
cycle and pathogenesis.107 
The first report of viruses being capable of using the UPS for their 
own benefit was the Scheffner et al. study of small DNA tumour 
viruses and their ability to modulate cell cycle.108 Since then, a 
number of other studies have proven that other viral families take 
advantage of ubiquitin conjugating system in their life cycle.109 From 
this perspective it became obvious that studies involving experiments 
with proteasome inhibition are crucial, as such treatment not only 
inhibits the UPS but also removes the free ubiquitin from the cell 
which would influence all cellular pathways involving ubiquitin. 
Proteasome inhibitors have been reported to inhibit many human 
viruses like herpesviruses, poxviruses, adenoviruses, influenza 
viruses, retroviruses, coronaviruses, paramyxoviruses, 
picornaviruses and rotaviruses.110 It has been shown in studies on 
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herpes simplex virus, influenza virus and adenoviruses, that ubiquitin 
modulates the first stage of viral replication- entry to the cell and viral 
capsid presentation to the target cell. 111112 Other stages of viral life 
cycle such as gene expression in Epstein-Barr113 virus or latency 
(property which enables the virus to cause lifelong infection process 
in host organism) in Kaposi's sarcoma-associated herpes virus 
(KSHV) are also affected by blocking the proteasome.114 
Viruses can also take over the ubiquitin conjugating system to 
modulate host innate immunity signalling. They stop the induction of 
Type I IFN by binding to its receptor.115 Viruses can challenge cellular 
ub-conjugating system by adjusting substrate specificity of ubiquitin 
ligases, changing which proteins are marked for degradation. Some 
viruses , especially large DNA viruses like poxvirus, are able to 
encode their own ubiquitinating enzymes, eg KSHV encodes two E3 
Ub ligases.116 
1.4.3. UPS- Ubiquitin Proteasome System 
Ubiquitin Proteasome Pathways are a crucial method of protein 
catabolism. Proteins destined for degradation by the proteasome are 
marked with ubiquitin in the ubiquitination process but it is not fully 
understood how proteins are targeted by the proteasome. In order to 
be recognised by a proteasome cap, a protein of interest must have 
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a chain of at least 4 ubiquitins attached to it, so it must be 
polyubiquitinated.117 Ubiquitin receptor proteins contain N-terminal 
ubiquitin like domain (UBL) and one or multiple ubiquitin associated 
domains (UBA). Proteasome caps recognise UBL domains and UBA 
is bound to ubiquitin by three-helix bundles.118 Because of the large 
number of cellular processes that UPS regulates, failing of the 
system may result in various diseases. These processes include: 
antigen processing, apoptosis, cellular cycle and division, organelles 
biogenesis, transcription and repair of DNA, development and 
differentiation, inflammation and immune response, response to 
stress and extracellular modulators and most importantly for this 
thesis- viral infection.119 The process can be divided into two steps: 
conjugation- attaching of the ubiqutin molecule, and degradation by 
the 26s proteasome consisting of the catalytic 20s core and the 19s 
regulator.120 Recently it has become apparent that ubiquitination also 
plays a major role in DNA repair and endocytosis. These newly 
discovered roles are dictated by the type of ubiqutin chain linkage, as 
well as number of ubiquitin molecules attached – mono versus 
polyubiquitinated proteins. Linkage of covalent bonds between 
ubiquitin and target protein can also be reversed in a process called 
de-ubiquitination or de-conjugation by de-ubiquitinising enzymes 
(DUBs) which makes the whole conjugation/de-conjugation system 
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very dynamic.121 The process has been recognised as crucial and 
Avram Hershko, Aaron Ciechanover and Irwin Rose who first 
discovered this were awarded the Nobel Prize for Chemistry in 2004.  
1.5. Aims and Objectives  
The work throughout my MPhil project was divided between two main 
objectives. The first set of experiments aimed to determine whether 
Nrf2 induction by sulforaphane might reduce replication of RSV in 
airway epithelial cells. Detailed description of these experiments 
together with results and discussion are included in Chapter 3. 
As Nrf2 is known to be differentially ubiquitinated, I first examined 
differential ubiquitination of Nrf2 in response to viral infection and 
then expanded this work to proteins selected from the proteomics  
including DDX21, MAVS, HMGB1, prohibitin, Annexin A1 and 
RPS10. These experiments aimed to validate data generated in the 
proteomics about whether these proteins change their level of 
ubiquitination following RSV infection, as well as answer the 
questions whether those changes in ubiquitination might result in 
protein turnover by the proteasome as part of host cell defence or 
viral manipulation of cellular process to aid viral replication. Detailed 
description of these experiments and their results together with 
discussion are included in Chapter 4. 
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2. Methodology 
2.1.  Cell Culture 
Cell types used during the project: 
- A549 cells (adenocarcinoma derived human alveolar basal 
epithelial cells) normally responsible for substance diffusion in the 
alveolar epithelium of the lungs and often used in RSV infection 
model.122  
- BEAS-2B (non-tumorigenic human bronchial epithelial cells)123 
- Hep2 cells (human epithelial type 2 cells) believed to come from 
human laryngeal carcinoma, associated with various autoimmune 
conditions.124 
Cells of each type were grown in Dulbecco’s Modified Eagles 
Medium (DMEM, Sigma), supplemented with 10% Foetal Calf Serum 
(FCS, Sigma), L-glutamine 200mM (Sigma), Penicillin 10,000units/ml 
(Sigma) and Streptomycin 10mg/ml (Sigma). Cells were grown in an 
incubator with 5% carbon dioxide (CO2) at 37°C. Every 2-3 days, 
dead cells were washed away with Phosphate Bovine Serum (PBS). 
Viable cells were harvested from the bottom of the flask and sub-
cultured with fresh media at a concentration of 1x10⁶cells/ml with 
15ml of fresh media in T75 flasks. All cell lines used in this study 
were mycoplasma free 
2.1.1. Seeding the cells. 
For each experiment stock cells were seeded as follows: 
Media was removed from T75 flasks of cells grown in an incubator. 
Cell monolayers were washed once with 5ml of PBS. 3ml of 0.25% 
trypsin 0.02% Ethylene-diamine-tetraacetic acid (EDTA, Sigma) was 
then added to flasks, which were then incubated at 37°C for 4-5 
minutes. Flasks were tapped to allow cells to detach from the bottom 
of the container. 7ml of FCS supplemented media (L- Glutamine, 
Streptomycin + Penicillin) was subsequently added to neutralise and 
deactivate trypsin. Cells were then centrifuged at 1600rpm at room 
temperature for 10 minutes and the supernatant removed and 
discarded.  
The pellet was resuspended in 1ml of supplemented media and the 
number of cells measured using a haemocytometer (Section 2.1.2). 
Depending on the specific experimental conditions used, cells were 
diluted with supplemented media and pipetted into each flask or well 
with a correct amount of media. 
2.1.2. Counting the cells 
Cells were counted using a haemocytometer as follows. Cell 
monolayers were washed once with PBS and scraped with a cell 
scraper. Contents of the dish were transferred into a universal 
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centrifuge tube and the dish washed twice with PBS, to make sure 
that the maximal number of cells from the dish was in the tube. Cells 
were spun down in a centrifuge for 10 minutes at 1600rpm at room 
temperature and the supernatant then discarded. Cell pellets were 
next resuspended in 1ml of supplemented media and 10µl of this 
solution put on the haemocytometer and viewed under a microscope. 
Cells in each of the big corner squares consisting of 16 little squares 
were counted and the number averaged. This gave a number 
equivalent to the cell count in 10⁴/ml. 
2.1.3. Harvesting the cells 
Depending on the experiment, cells were harvested at 4, 24 or 48 
hours, using the following method. 
Cells were washed once with PBS. Small amounts of PBS (according 
to the surface of the dish, eg. 0,5 ml for a well in a 6 well plate, 3 ml 
for a T75 flask) were added to each flask and cells carefully scraped 
from the bottom of the dish. The whole surface of the dish was 
scraped, in order to maximise the number of cells collected. Scraped 
cells in PBS were transferred into a 10 ml universal centrifuge tube 
and the dish (flask/well) washed twice with PBS, to maximise the 
number of cells collected. Tubes were spun in a centrifuge for 10 
minutes at room temperature at 1600 rpm. Supernatant was taken off 
and discarded and the cell pellet resuspended in 1ml of PBS. 
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According to the experiment and desired number of samples, cells 
were divided between micro centrifuge tubes in 100µl of solution, and 
spun again in a microfuge for 10 minutes at 1330 rpm. Supernatant 
was taken off and discarded, leaving dry pellets which were stored in 
labelled tubes at -30°C for future use. 
2.2. RSV preparation 
All virus stock used for the experiments in my project was made 
using the following method.  
 
2.2.1. RSV propagation 
Day one: 
Hep 2 cells were seeded at 3x10⁴ cells/cm in 15 ml of supplemented 
media in a T75 flask and incubated at 37°C in 5% humidity for 24 
hours (or longer if not 50% confluent after 24 hours). 
Day Two: 
Once 50% cell confluence was reached, media was removed and 
cells were washed twice with 5ml PBS. 500µg of RSV stock was 
placed in 3ml of serum-free media and added to the flask with cells. 
Cells were then incubated on a rocker for two hours at 37°C to make 
sure that virus particles spread evenly over the whole flask surface. 
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After two hours, 13ml of supplemented media was added to the flask, 
which was then left overnight in the incubator at 37°C. 
Day Three: 
Flasks were inspected under the microscope and media changed. 
Flasks were again stored in the incubator at 37°C overnight. 
Day Four: 
Forty-eight hours post-infection, cells were harvested as described 
above using a cell scraper. These steps were carried out rapidly with 
the samples kept on ice to ensure that the virus maintained its 
integrity and did not degrade.  
In a cooled centrifuge at 4°C, harvested cells were spun down at 
1600rpm for 10 minutes in 50ml tubes. Supernatant was taken off 
and placed in separate tubes on ice. 2ml of the removed supernatant 
was used to resuspend the cell pellet and mixed by vortex. Solution 
was evenly split into two micro centrifuge tubes tubes and kept on 
ice. Cells were then lysed using a 25 gauge needle and 1ml syringe 
for ten passes, to burst cells open and release RSV. Next, 500µl of 
solution was transferred to four pre-labelled cryovials and snap 
frozen in liquid nitrogen. Vials were then stored at -70°C.  
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2.2.2. RSV Plaque Assay 
In order to establish the number of virus Plaque Forming Units (PFU) 
per ml of solution, the following method was used for each batch of 
virus in this project. 
Day One: 
Using 27 wells of a 96-well flat bottomed plate, 2 x 10⁴/ml A549 cells 
were seeded per well and grown in supplemented DMEM media in 
an incubator for 48hrs at 37°C.  
Day Three: 
After 48 hours, serial dilution of RSV was prepared using the 
following method. 
Micro centrifuge tubes  tubes were placed on ice to prevent virus 
degradation. 500µl of serum free DMEM media was placed in one 
tube and 250µl in seven others. A water bath was warmed to 37°C. A 
vial of RSV was removed from the freezer, and snap thawed in 
water. In order to achieve 1:100 dilution in the first tube, 5µl of virus 
solution was added to the media and mixed well. 250µl out of this 
solution was then transferred to the second tube and doubling 
dilutions prepared until the last, eighth tube.  
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Cell monolayers in each well were washed once with PBS, and 50µl 
of each dilution of virus added to wells in triplicate going horizontally. 
Plates were incubated at 37°C. After two hours, 100µl of 
supplemented media was added to each well and plate put in the 
incubator until the next morning. 
Day Four: 
Each well was washed once with 100µl of PBS and cells fixed for 20 
minutes at room temperature with 100µl of 100% methanol 
containing 2% hydrogen peroxidase. Using a multi-channel pipette, 
cells were washed gently with 100µl of PBS per well. Pipetting the 
solution directly onto the cell monolayer was avoided, in order not to 
disrupt it.  
After 20 minutes, 100µl of goat anti-RSV antibody (Bio-rad), diluted 
1/200 with PBS/1% Bovine Serum Albumin (BSA), was added to 
each well and incubated at room temperature for one hour. Each well 
was then washed twice with 100µl PBS/1% BSA. 100µl of extravidin 
peroxidise (2mg/ml, Sigma-Aldrich) diluted 1/500 with PBS was 
subsequently added and left for 30 minutes at room temperature.  
Cells were washed twice with 100µl PBS/1% BSA. A Sigma-Fast 
Red Tablet (TR/Naphthol AS-MX) was diluted in 5 mls of PBS. 50µl 
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of this solution was then added to each well for approximately 10 
minutes to stain plaques.  
After the plaques appeared, PBS was added in order to stop reaction 
and the plaques were counted. Dilutions which produced around 
100-200 plaques per well were selected and each replicate was 
counted to estimate the average value. In order to decrease the 
possibility of counting error, plaques in dilutions above and below 
were also counted and the number averaged. The whole process 
was repeated by two people separately and the values compared 
and averaged. The RSV plaque assay is shown in Figure 2.1.  
Figure 2.1. Microscopic image of RSV plaques formed during the 
plaque assay protocol. 
 
RSV plaques indicated with lines. 
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In order to count the PFU per ml of solution, the following formula 
was used: 
Number of plaques x dilution (eg. 100, 200, 400 etc) x 20 
The dilutions for each well were as follows: 
Dilution 1- 1/100 
Dilution 2- 1/200 
Dilution 3- 1/400 
Dilution 4- 1/800 
Dilution 5- 1/1600 
Dilution 6- 1/3200 
Dilution 7- 1/6400 
Dilution 8 1/12800 
In order to use the right amount of virus for each experiment, 
Multiplicity of Infection (MOI) was calculated for each batch. Ratio 
between the number of cells in a particular dish and the number of 
RSV particles was calculated by dividing the number of RSV particles 
over the known cell number in the well/flask. 
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2.2.3. RSV Infection 
BEAS- 2B and A549 cells were seeded in the correct sized plates or 
flasks as explained in Section 2.2.1. Cells were usually ready to be 
infected after 48 hours in the incubator when they reached 90% 
confluence. The correct number of vials was removed from the -70°C 
freezer and snap thawed in water bath at 37°C. Those steps were 
carried out promptly in order to avoid RSV degradation. Cells were 
washed once with PBS and new media added to the flasks. Correct 
amount of virus for each plate or flask was then diluted in serum free 
media and added to the dishes with cells. 
Depending on experiment, cells were left in the incubator at 37°C 
until the harvest time (usually 4, 24 or 48 hours). 
2.3. BCA protein Assay 
The bicinchoninic acid assay (BCA assay) or the Smith’s assay was 
carried out on the samples destined for western blotting, in order to 
assess protein concentration in each sample and ensure that protein 
loading on gel was even. Samples were prepared in the following 
micro plate procedure and protein concentration calculated by a 
colorimetric scanner.125 Pierce™ BCA Protein Assay Kit produced by 
Life Technologies was used in this project. 
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Samples for the procedure were prepared by adding 100µl of 1% 
protease inhibitor (Sigma) and 99% protein extraction reagent 
(CytoBuster™ Protein Extraction Reagent) to each dry pellet taken 
out of the freezer. A total of eight standards were made by serial 
dilution of 500µl of Albumin Standard Ampules (2mg/mL, 10 x 1 mL) 
in each tube, giving the concentrations of 2000, 1000, 500, 250, 125, 
62.5, 31.25 and 0. 25µg of each sample, and standard was pipetted 
into a 96 microplate well in a working range of 20-2000 . 25µl of 
each sample was added in duplicates horizontally on the plate, 
diluting the samples as appropriate in sterile distilled water (23µl 
H2O+ 2µl sample= 1:12.5 dilution) 
Working reagent was made up to 1:50 dilution, 1 part of solution B 
(green) and 50 parts of solution A (colourless). 200 µl of this mixture 
was carefully added to each well and plate left for 30 seconds on a 
plate shaker in room temperature to mix thoroughly. Each plate was 
then covered and incubated at 37°C for 30 minutes. After 30 
minutes, the plate was left on the bench in room temperature to cool 
down for about 5 minutes and read with a plate reader at or near 562 
nm. 
The amount of sample loaded on the western blot gel was adjusted 
accordingly to the least concentrated sample. 
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2.4. RNA extraction 
Extraction and isolation of RNA methodology was carried out as 
described by the manufacturers of TRIzol® reagent (Life 
Technologies) and is described below. 
2.4.1. Homogenising sample 
Culture supernatants were taken off from the cells and stored at -
20°C for future experiments. Samples were homogenised using 
TRIzol® reagent (a monophasic solution made up of phenol and 
guanidine isothiocyanate)126. 
0,5ml of TRIzol® was used per well containing 5-10x10⁶ cells or per 
dry pellet stored in a freezer.  This amount of TRIzol® was used to 
make sure that there was no DNA contamination within the isolated 
RNA. Each sample was carefully pipetted up and down a number of 
times to ensure that cells from the whole surface of the well were 
taken into the solution. The tubes with dry pellets were mixed using 
vortex for 2 minutes and each of the samples were placed in an 
individual, labelled tube. 
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2.4.2. Phase separation and precipitation 
Samples were incubated for five minutes at room temperature, to 
allow nucleoprotein complexes to completely dissociate. 200µl of 
chloroform was the added to each sample, which were then mixed 
thoroughly by vortex for 10 seconds and centrifuged at 13,300rpm for 
15 minutes at room temperature.  
Samples separated into the following three layers: 
1) Bottom pink phenol-chloroform phase 
2) Middle interphase 
3) Top colourless aqueous phase with the RNA 
The top layer was carefully removed using P200 pipette at 45° angle. 
Removing the middle or bottom layer was avoided, as that would 
result in DNA contamination of the sample. Contents of each tube 
were placed in new tubes containing 250µl of isopropanolol with 
corresponding labels. Samples were then mixed by vortex and 
placed in -70°C freezer for ten minutes, before being centrifuged at 
13,300rpm for fifteen minutes. Putting samples in the centrifuge in 
the exact same position, allowed for the gel-like pellet formed at the 
bottom of the tube to be easily identified. 
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2.4.3. RNA wash 
Supernatant was removed from each tube, carefully avoiding 
touching the pellet with the pipette tip and discarded. 200µl of 70% 
ethanol was added to each tube and mixed by vortex for fifteen 
seconds. Samples were microfuged at 13,300rpm for 10 minutes. 
Supernatant was then removed carefully with the pipette tip and the 
tubes left open to make sure that the pellets air dry for approximately 
fifteen minutes. Once the pellets were dry, they were resuspended in 
20µl of sterile, nuclease-free water. 
2.5. Reverse transcription 
Complementary DNA (cDNA) was prepared with High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) using random 
primers. To each 200 µl tube labelled accordingly, the following 
components were added from the kit: 
2µl 10x RT Buffer 
1µl 25x dNTP Mix (100 mM) 
2µl 10x RT Random Primers 
5.2µl sterile, nuclease-free water 
0.8µl of Multiscribe Reverse Transcriptase 
10µl of the corresponding sample (RNA solution). 
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The contents of the tubes were reverse transcribed at 37°C for one 
hour.  
2.6. PCR 
PCR (Polymerase-chain reaction) is a method used to amplify the 
desired region of DNA, with the purpose of making multiple copies of 
that sequence. In this project, PCR was used to assess the presence 
and amount of RSV in the samples.  
 
2.6.1.  Principles of PCR 
The process of PCR amplification can be divided into four phases: 
1. Baseline - no signal is released during the cycles because the 
amplification level is too low to be detected by the quantitative 
PCR (qPCR).   
2. Exponential - amplicons are quantified, signal is above the 
detection level and the product should double exactly every 
cycle to produce the number of amplicons if the assay is 100% 
efficient.  
3. Linear - the efficiency of amplification is reduced to less than 2 
per cycle because the amount of reagents goes down with 
their use. 
4. Plateau - after all the reagents have slowly been used, the 
reaction ceases and no more products are synthesised. 
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During the second phase, the threshold level line is set. This line is 
the point at which fluorescent signal is detected against the 
background. Cycle number is quantified when the sample signal 
goes above the line and that gives the result obtained from q PCR, 
called the Cycle Threshold (Ct).127 
2.6.2. Reagents and processing of PCR 
TaqMan assay kit by Applied Biosystems was used for the qPCR in 
this project. For every PCR, RSV and the housekeeping gene (L32) 
TaqMan probes were used. The probes are linear oligonucleotides, 
which match specific gene sequence located between forward and 
reverse primers. Each of the probes was diluted in TaqMan gene 
expression Master Mix, which contains DNA polymerase. It allows 
copying the strand of the cDNA template after the primers have 
attached onto it. The PCR plate was prepared when reverse 
transcription was taking place, using a 96-well plate which fits into 
the LightCycler 480 machine.  
For the Life Technology probes, 1.25µl of readymade probe was 
mixed with 12.5µl of TaqMan gene expression master mix (Applied 
Biosystems) per each well. RSV probe was designed on the basis of 
Dewhurst-Maridor et al paper128 and ordered from Sigma. For every 
PCR, it was mixed using three different primers and Nuclease-free 
water as follows: 
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RSV AF (forward) 10µl 
 RSVAR (reverse) 10µl 
 RSVN-TAQ 40µl 
 RNA free water 40µl 
1.25µl of this mixture was used in the same way as Life Technology 
probes, with 12.5µl of TaqMan gene expression master mix per each 
well. 13.75µl of probe mix (1.25 probe and 12.5 master mix) and 
11.25µl of diluted cDNA (20µl of cDNA and 180µl of Nuclease free 
water) was pipetted into each well required for the PCR, making up 
25 µl in total. The duplicates of samples were made for each of the 
probes, so that the values can be averaged during the analysis in 
order to limit pipetting error. L32 housekeeping gene was used as a 
control, as RSV infection does not affect its expression in A549 cells. 
A plate was carefully covered with film and spun down in a microfuge 
for 15 seconds to ensure all the liquid was at the bottom of the wells. 
Finally, the plate was placed in the LightCycler 480 Real-Time pCR 
machine and read with the MxPro software. 
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2.7. Western blots  
Western blotting, also known as immunoblotting, is a widely 
recognised scientific technique, used to isolate a single protein of 
interest from a biological sample. Briefly, the technique aims to 
transfer biological samples from gel onto a membrane by 
electrophoresis and then detect proteins on the surface of this 
membrane. 
2.7.1. Background and theory 
The process can be divided into two steps: 
1. Tissue preparation - cells in a sample are broken down by 
various mechanical and biochemical techniques, such as 
centrifugation and by using buffers. Protease and 
phosphatase inhibitors are added to the sample at this stage, 
to prevent digestion of proteins by enzymes within the sample. 
This process is carried out at low temperatures (samples are 
kept on ice), to avoid protein denaturation and degradation. 
2. Gel electrophoresis - proteins are separated according to their 
isoelectric point, molecular weight or electric charge. Samples 
are then loaded on gel next to a standard, which will allow 
identifying molecular weight of proteins by creating visible 
coloured bands.  Voltage is applied along the gel and proteins 
start to migrate through it at different speeds, depending on 
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their size and weight. These different rates allow for the 
proteins to be separated into bands within each lane.  
The proteins are then moved from the gel on to nitrocellulose/ 
polyvinyle membrane, to make them accessible for antibody 
detection by electroblotting. The membrane is next blocked, in order 
to avoid interaction between membrane and the antibody used for 
protein detection. Protein in dilute solution attaches to the membrane 
in all places where target proteins have not attached. When the 
antibody is added, it attaches to the binding site of the specific target 
protein only. In order to detect protein, the membrane is probed with 
modified antibody linked to a reporter enzyme. When exposed to 
appropriate substrate, the enzyme drives a colorimetric reaction and 
produces colour. First, the primary antibody binds to protein. Next, 
the secondary antibody, which has an enzyme visible under 
chemiluminescence, binds to the primary antibody. The enzyme most 
commonly used is horseradish peroxidise and produces 
luminescence in proportion to the amount of protein present.  
2.7.2. Protocol 
Cells were previously isolated and stored as dry pellets.  
The required amount of lysis buffer was prepared and 100µl was 
added to each dry pellet in an Micro centrifuge tubes  tube. 
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Lysis buffer: 
89% Bromophenol blue (Sigma) 
10% DTT-(Dithiothreitol) (Sigma) 
1% Protease inhibitor (Thermo-Scientific) 
Micro centrifuge tubes were boiled in a heating block for 3 minutes at 
100°C and mixed by vortex every 60 seconds. Samples were loaded 
on to the gel, one sample for each numbered well, leaving the first 
well empty to be loaded with standard (Bio-rad). 
The pre-cast gel (Bio-rad) was removed from the storage pouch and 
the comb taken out gently, not to disrupt the wells. Gel cassette was 
placed in electrophoresis module and tank filled with Running Buffer.  
Running Buffer: 
Tris Base 3,03g (Fisher) 
Glycine 14,1g (Fisher) 
Sodium dodecyl sulphate (SDS) 1g (Bio-rad) 
Sterile water- up to 1L 
Leads were connected to the tank and voltage was set to 160 volts. 
Gel was run for approximately 40 minutes, but this time was adjusted 
according to the size of band of interest.  
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The gel was then separated from the plates by slicing along the sides 
of gel cassette and the edges were cut, so that area containing 
proteins fits onto Polyvinylidene fluoride (PVDF) membrane. The gel 
was placed on membrane (Trans-Blot Turbo Mini PVDF Transfer 
Pack, Bio Rad) between two filter papers soaked in transfer buffer 
(already prepared in a pack). The membrane was carefully rolled 
between two filter papers, to remove air bubbles and allow an even 
transfer of proteins from membrane onto gel. A cassette was locked, 
placed in a semi dry transblot machine and run on mixed Molecular 
Weight (MW) protocol. After 7 minutes, the cassette was taken out of 
the machine and blotting sandwich disassembled. PVDF membrane 
was cut and after discarding the areas not containing transferred 
proteins, immediately placed in a dish with blocking buffer (TBS-T + 
5% milk). These steps were carried out very promptly, to prevent the 
membrane from drying out. 
The membrane was incubated with a blocking buffer for one hour at 
room temperature, under gentle agitation on orbital shaker. Next, the 
membrane was washed with TBS-T (Tris-Buffered Saline and Tween 
20) on an orbital rocker, at room temperature, twice for 30 seconds, 
twice for 5 minutes and 1 time for 15 minutes. Primary antibody 
solution was made using TBS-T and 5% milk. The membrane was 
then incubated with the solution overnight at -4°C under gentle 
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agitation. The whole area of the membrane was covered with a 
solution and the dish covered with lid or parafilm, so that the solution 
does not evaporate. The names and concentrations of all primary 
antibodies can be found in Table 1.  
The next morning, primary antibody was removed and the membrane 
washed, in the same way as previously described. The membrane 
was incubated with secondary antibody solution using TBST and 
milk, with addition of secondary standard component (Bio-rad) at the 
concentration of 1:5000 and incubated for 1 hour at room 
temperature on orbital shaker. The membrane was afterwards 
washed with TBST using the exact same protocol (2x 30 seconds, 
2x5 minutes, 1x 15minutes). After washes, the membrane was 
carefully transferred onto cling film. Chemiluminescence solution was 
prepared by adding 400µl of solution A and B into one Micro 
centrifuge tubes  tube and carefully mixing together 
(Chemiluminescent substrate, Li-Cor). This solution was then 
pipetted onto the protein side of the membrane, ensuring that it 
covers membrane evenly and incubated for 5 minutes. Excess 
chemiluminescence was removed and membrane placed face down 
on scanner (Li-cor). The blot was scanned using Image Studio Light 
Version Software and membrane stored in TBST or re-probed with 
different primary and secondary antibody if needed.  
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2.8. Immunofluorescence  
Protocol for this procedure was based on the technique used by Calo 
et al to stain for DDX21.129 
A549 cells were seeded into 24-well plates, containing 12-mm glass 
coverslips and cultured for 24 hours in supplemented DMEM media. 
Cells were infected with RSV at multiplicity of infection (MOI) of 1:1 
for 4 hours. After that, cover slips were washed once with 1ml of PBS 
per well and transferred to a new, clean 24-well plate. Cells were 
fixed in 4% paraformaldehyde for 10 minutes at room temperature 
and washed three times for 5 minutes with sterile PBS. Cells were 
then fixed with ice cold methanol (previously placed in -80°C freezer 
and transferred onto ice) for 2 minutes and washed twice with PBS, 
each wash lasting 5 minutes. Cells were then permeabilised in PBS 
containing 0.3% (v/v) Triton X-100 for 5 minutes and blocked in PBT 
buffer (PBS with 1% BSA, 0.1% Triton X-100(v/v), 0,05% sodium 
azide (w/v)) overnight at 4°C.  
The next morning, coverslips were incubated in PBT with 
corresponding antibody for 2 hours at room temperature. The 
concentrations of antibodies were acquired from the products’ 
datasheets and are listed in Table 1 together with products’ codes.  
After the incubation period, cover slips were washed three times for 5 
minutes with PBT and incubated with corresponding secondary 
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antibodies for one hour. The cells were washed 3 times for 5 minutes 
with PBT and two times for 5 minutes with PBS. Finally, cells were 
mounted onto glass slides using VECTASHIELD mounting medium 
with DAPI. 
2.8.1. Confocal Microscope 
Slides were viewed under confocal microscope. Three pictures of 
each slide were taken, one using low power lens and two using high 
power lens with immersion liquid (Type F Immersion liquid, Leica). 
Colour threshold was first adjusted to corresponding control antibody 
(anti-mouse for RPS10 and Annexin A1 and anti-rabbit for DDX21) to 
avoid creating false positives.  
2.9. Immunoprecipitation 
Immunoprecipitation is a technique used to precipitate antigen out of 
solution, using antibodies that specifically bind to the proteins of 
interest. This technique allows the isolation of a single protein out of 
mixture and requires solid substrate to bind to antibody at some point 
during the procedure. In this case, magnetic beads were the 
substrate. The immunoprecipitation of samples used for the western 
blot analysis was carried out with Dynabeads® Protein G 
Immunoprecipitation Kit, according to the protocol provided by the 
manufacturer and involved the following steps: 
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2.9.1. Antibody binding 
A bottle of Dynabeads (ThermoFischer Scientific) was placed on a 
rotating shaker for 5 minutes to completely resuspend the beads. 
50µl of solution was added to the new, labeled Micro centrifuge tubes  
tubes and put on magnet to remove supernatant. Beads were then 
resuspended in 200 µl of Antibody Binding and Washing Buffer and 
the antibody of choice (1.25 µl of antibody per each tube).Tubes 
were incubated with rotation at room temperature for 10 minutes. 
Supernatant was removed again by placing tubes on a magnet and 
the beads-antibody complex washed with 200 µl of Antibody Binding 
and Washing Buffer. 
2.9.2. Antigen immunoprecipitation 
Supernatant was removed by placing the tubes on the magnet and 
50µl of antigen containing sample was added to the beads-antibody 
complex and carefully resuspended by pipetting. This solution was 
incubated for 30 minutes with rotation at room temperature, to allow 
binding of maximal number of antigen-antibody particles. 
Supernatant was then removed and put into new tubes, with 
corresponding labels. Beads-antibody-antigen complex was washed 
3 times with 200µl of washing buffer and mixed carefully by pipetting 
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each time. After that, tubes were either frozen at -30°C with 100 µl of 
the washing buffer or immediately used for western blot.  
Table 1. Names and product codes of antibodies used for Western 
blots and immunofluoroscopy. 
Name of the antibody Company and product 
code 
Concentration used 
Anti- beta actin Abcam Ab8226 1 in 5000 
Goat Anti-Mouse IgG 
HRP 
R&D HAF007 1 in 1000 
Anti- Nrf2 Abcam Ab62352 1 in 2000 
Human HMGB1 R&D MAB1690 1 in 1000 
Anti-MAVS Abcam Ab25084 1 in 10000 
Goat Anti- Rabbit IgG 
HRP 
R&D HAF008 1 in 1000 
Anti- Annexin Abcam Ab118060 1 in 2000 
Anti- DDX21 Abcam Ab182156 1 in 5000 
Anti- RPS10 Abcam Ab151550 1 in 5000 
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3. Nrf2 signaling in RSV infection 
3.1. Introduction 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), transcription factor 
regulating antioxidant protein expression, has an important role in 
preventing pulmonary oxidative damage. The protective pathway is 
believed to involve antioxidant response element (ARE)-mediated 
gene induction. Animal studies, show exacerbated lung inflammation 
and damage in Nrf2 deficient animals compared to those that 
express Nrf2. It has been suggested that Nrf2 induction may offer a 
future treatment approach for RSV disease.130 Sulforaphane is a 
potent, naturally occurring inducer of Nrf2 found in vegetables such 
as broccoli.131 In this study, I sought to determine whether Nrf2 
induction by sulforaphane might reduce RSV replication in airway 
epithelial cells. (Section 1.1) 
The Hypothesis examined was: Induction of Nrf2 in RSV infected 
airway epithelial cells inhibits RSV replication. 
Specific aims which lead to answering the hypothesis were: 
1) To determine what is the best antibody to detect Nrf2. 
2) To determine what is the best cell line to conduct experiments 
with Nrf2. 
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3) To determine what is the best concentration of sulforaphane to 
induce Nrf2. 
4) To determine what is the best time to add sulforaphane to 
samples and its kinetics of expression. 
5) To determine whether sulforaphane induces expression of 
Nrf2 
6) To determine whether induction of Nrf2 in bronchial epithelial 
cells inhibits RSV replication. 
 
3.2. Results  
Western blot and Real Time q-PCR analysis results. 
3.2.1. Validation of antibodies. 
While choosing reagents for the experiment, it became apparent that 
there is a wide variety of companies offering different anti-Nrf2 
antibodies on the market. It was important to choose one giving most 
reliable results. On the basis of conversations with colleagues 
conducting research on Nrf2 and a literature search, 3 different 
antibodies were chosen for the initial optimisation. Each antibody is 
produced by a different, widely recognized company (Abcam, R&D, 
Santa Cruz). The Santa Cruz antibody was kindly provided by Prof 
Chris Sanderson from the University of Liverpool others were 
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purchased from the supplier. Figure 3.1. shows western blot analysis 
of the comparison of antibodies. 
Figure 3.1. Anti-Nrf2 antibodies comparison on BEAS- 2B cells. 
a) Abcam antibody 
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b) Santa Cruz antibody 
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c) R&D antibody 
 
Western blot analysis showing changes in expression and pattern of Nrf2 bands 
detected by 3 different anti-Nrf2 antibodies produced by a) Abcam b) Santa Cruz 
and c) R&D. Each antibody was used on the same set of samples at concentration 
suggested by the manufacturer on the data sheet. The correct band for Nrf2 is 
marked with an arrow on the first blot (~100 kDa). Actin band of 42kDa was 
provided as loading control. Molecular weight markers are presented on the left 
side of blots. 
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Results show different pattern of detected Nrf2 bands for each 
antibody. Santa Cruz and Abcam antibody detected multiple 
additional bands most probably due to non-specific binding. R&D 
antibody detected bands at the level of ~60/70 kDa, which are not 
recognizable as Nrf2 bands. 132 Based on literature search and 
opinion of experts in the field of Nrf2 research, antibody selected for 
the future experiments was rabbit monoclonal Anti-Nrf2 abcam 
(ab62353) antibody which detected a desired band of 100kDa. 
(Research papers further discussed in Section 3.3). 
3.2.3. Time course 
In order to establish the optimal time for Nrf2 induction by 
sulforaphane, time course experiment was carried out on RSV 
infected and non-infected BEAS 2B cells. Both experimental 
conditions were used to show whether time needed to induce Nrf2 
expression by sulforaphane changes with infection. Based on the 
results from previous experiments, cells were incubated with 5nM of 
sulforaphane. Time course results on non-infected cells are shown in 
Figure 3.2 and on both conditions in Figure 3.3.  
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Figure 3.2. Induction of Nrf2 by sulforaphane in non-infected BEAS 
2-B cells. Time course experiment. 
 
Western blot analysis of changes in expression of Nrf2 by BEAS 2-B cells after 
stimulation with 5 nM of Sulforaphane for various amounts of time, ranging from 0 
to 24 hours. Expression of Nrf2 was analysed with rabbit monoclonal Anti-Nrf2 
abcam (ab62353) antibody.  Actin band of 42 kDa provided loading control.  
 
 
 
 
 
 
 
 84 
 
Figure 3.3.  Induction of Nrf2 by sulforaphane in non-infected and 
RSV infected BEAS 2-B cells. Time course experiment. 
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Results from Figure 3.2. show highest expression of Nrf2 in sample 
stimulated with sulforaphane for 4 hours (non-infected cells). In 
Figure 3.3., the most enhanced bands are apparent in samples 
stimulated for 1 and 4 hours. Densitometry results show highest 
expression of Nrf2 in samples incubated with sulforaphane for 2 
hours for infected cells and 1 hour for non-infected cells. 4 hours was 
chosen as the time for maximal induction in further experiments.  
An important finding in Figure 3.3., is that the amount of Nrf2 in 
infected cells does not necessary increase in comparison to control. 
As it was not known at what time point Nrf2 expression may affect 
RSV replication further experiments, included stimulating cells with 
sulforaphane before, as well as after RSV infection. Results are 
shown in Figure 3.4.  
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Figure 3.4. Expression of Nrf2 by BEAS-2B cells with sulforaphane 
stimulation pre and post RSV infection.  
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In samples treated with sulforaphane, increase in Nrf2 expression is 
apparent. The biggest visible increase is 22 hours post infection, 2 
hours before sample collection. Densitometric analysis confirms 
these results. This time point was used in further experiments. 
3.2.2. Choice of the cell line 
It was important for experiments to be optimised. Initial choice of cell 
lines and reagents, as well as their concentration and time of 
exposure etc. were based on literature search and then optimised in 
this study. Firstly, A549 and BEAS-2B cell lines were compared to 
assess induction of Nrf2 with increasing doses of sulforaphane. 
Figure 3.5. shows this comparison.  
Figure 3.5. Comparison of Nrf2 induction by sulforaphane in A549 
and BEAS-2B cell lines. 
Western blot analysis showing changes in expression of Nrf2 in A549 and BEAS2B cells, with and 
without treatment with sulforaphane. Cells were treated with increasing doses of sulforaphane ranging 
from 0 to 20 nM for 4 hours. Expression of Nrf2 was analysed with rabbit monoclonal anti-Nrf2 abcam 
(ab62353) antibody. Actin band of 42 kDa provided loading control. 
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Results show continuous expression of Nrf2 in A549 cells, despite 
the change of experimental conditions. In BEAS-2B cell line, 
expression of Nrf2 is induced by sulforaphane in comparison to 
control sample. BEAS-2B was decided to be the cell line of choice for 
further experiments and would allow a comparison between cells with 
and without NRF-2 induction by sulforaphane. This experiment was 
next repeated on BEAS-2B cells to choose optimal concentration of 
sulforaphane. Results are presented in Figure 3.6. 
 
Figure 3.6. Sulforaphane dose response on BEAS-2B cell line. 
 
Western blot analysis showing changes in the amount of Nrf2 expressed by BEAS-2B cells after 
stimulation with different doses of sulforaphane, ranging from 0 to 20 nM for 4 hours. Expression of Nrf2 
was analysed with rabbit monoclonal Anti-Nrf2 abcam (ab62353) antibody. Actin band of 42 kDa 
provided loading control.  
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The strongest signal was detected in samples treated with 
sulforaphane at concentrations between 2 and 5nM. Concentration of 
sulforaphane chosen for further experiments was decided to be 5nM. 
3.2.4. The effect of Nrf2 induction by sulforaphane on RSV 
expression. 
BEAS-2B cells were infected with 1:1 concentration of RSV and 
treated with 5nM of sulforaphane pre and post infection at different 
time points. Amount of Nrf2 was measured by western blot analysis. 
Sulforaphane was added to samples 4 hours prior to viral infection. 
All cells were harvested at 24 hours, excluding controls harvested at 
0 hours (just before RSV infection of remaining samples),to confirm 
induction of NRF-2. Figure 3.7. includes a diagram presenting steps 
of experiment. Figure 3.8. demonstrates results of this experiment on 
a western blot. 
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Figure 3.7. Design of the experiment. 
 
Diagram showing steps of the experiment in chronological manner. Cells were 
infected 4 hours prior to RSV infection at 0hrs. Cells were infected with 1:1 MOI of 
virus and harvested at 24 hours, excluding non-infected controls harvested at 0 
hours. 
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Figure 3.8. Induction of Nrf2 expression by BEAS-2B cells using 
sulforaphane (1). 
 
Western blot analysis showing changes in the expression of Nrf2 and amount of RSV in BEAS-2B cells 
treated with sulforaphane. Cells were treated with 5nM of sulforaphane 4 hours prior to infection and 
infected with 1:1 MOI at 0 hours. Samples were harvested at 24 hours, excluding non-infected samples 
harvested at 0 hours. Expression of Nrf2 was analysed with rabbit monoclonal anti-Nrf2 abcam 
(ab62353) antibody. Expression of RSV was analysed with polyclonal anti-RSV antibody (7950-0104 
Bio-rad). Actin band of 42 kDa provided loading control.  
 
Western blot analysis confirmed that samples infected with RSV 
contain virus and that there is no contamination of control samples. 
No difference in RSV protein expression was observed between 
sulforaphane treated and non-treated samples.   There is no change 
in the darkness of Nrf2 band between non-infected samples 
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harvested at 24 hours. The strongest signal is detected in a non-
infected sample treated with sulforaphane. Nrf2 band disappears in 
samples infected with RSV. Experiment was repeated to determine if 
this would be a consistent finding or if any pattern emerges. The 
results are shown in Figure 3.9. 
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Figure 3.9. Induction of Nrf2 expression by BEAS-2B cells using 
sulforaphane (2). 
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Antibody detects the correct size of Nrf2 band. Signal is stronger in 
non-infected samples treated with sulforaphane in comparison to 
control without treatment and weaker in infected sample without 
treatment in comparison to infected control, as previously. In the 24 
hours control sample, signal from Nrf2 band decreases significantly. 
Densitometric analysis confirms these results. 
Experiment was repeated once again. Results are shown in Figure 
3.10. 
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Figure 3.10.  Induction of Nrf2 expression by BEAS-2B cells using 
sulforaphane (3).  
 
Western blot analysis showing changes in the expression of Nrf2 and amount of RSV in BEAS-2B cells 
treated with sulforaphane. Cells were treated with 5nM of sulforaphane 4 hours prior to infection and 
infected with 1:1 MOI at 0 hours. Samples were harvested at 24 hours, excluding non-infected samples 
harvested at 0 hours. Expression of Nrf2 was analysed with rabbit monoclonal anti-Nrf2 abcam 
(ab62353) antibody. Expression of RSV was analysed with polyclonal anti-RSV antibody (7950-0104 
Bio-rad). Actin band of 42 kDa provided loading control.  
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Densitometric analysis of this western blot bands intensities was performed using Li-cor Imgae Studio 
Lite Versio 3.1. software. Nrf2 bands were normalised to loading control actin band and are presented 
in the graph above. Cells were treated with 5nM of sulforaphane 4 hours prior to infection and infected 
with 1:1 MOI at 0 hours. Samples were harvested at 24 hours, excluding non-infected samples 
harvested at 0 hours. 
 
Signal from Nrf2 band is weak and it is difficult to notice any 
difference between the samples. Results are different to two previous 
blots: there is no increase in Nrf2 in sulforaphane treated samples or 
decrease in infected samples and no pattern is emerging. 
Densitometric analysis shows increase in Nrf2 in non-infected 
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sample without treatment, harvested at 24 hours which is difficult to 
explain. 
To examine if induced sulforaphane affected RSV protein expression 
an experiment with Nrf2 induction with sulforaphane pre and post 
infection was repeated and western blot probed with anti-RSV 
antibody. The results are shown in Figure 3.11. 
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Figure 3.11. Suppression of RSV replication by sulforaphane in 
BEAS-2B cells (1). 
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Signal from infected samples is stronger in comparison to non-
infected controls. Difference in the amount of RSV or pattern of 
bands between the infected samples is not apparent. In order to see 
whether this result can be reproducible, it was decided to repeat this 
experiment with two additional samples, both harvested at 48 hours 
and one of them treated with sulforaphane for 2 hours. Results are 
shown in Figure 3.12. 
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Figure 3.12. Suppression of RSV replication by sulforaphane in 
BEAS-2B cells (2). 
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Results of this western blot analysis, similarly to previous 
experiments do not show a difference between samples apart from 
the last sample (treated with sulforaphane for 2 hours and harvested 
48 hours post infection), where bands are weaker. This result 
however is likely to be a result of uneven protein loading (Further 
discussed in section 2.3.). 
The amount of virus in samples was next analysed with Real Time 
PCR. Figure 3.13 shows PCR results of samples corresponding to 
the western blot in Figure 3.11.  
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Figure 3.13.  RSV expression in comparison to L32 in BEAS-2B cells 
treated with sulforaphane corresponding to western blot in Figure 
3.13. 
 
PCR analysis of the  increase of RSV in comparison to housekeeping gene (L32) in BEAS-2B cells 
treated with 5nM of sulforaphane pre and post infection for various amount of time, ranging from 1hr to 
22hours. Cells infected with 1:1 MOI of RSV and treated with RSV for various amounts of time. 
 
 
No RSV signal was detected in negative control. The amount of RSV 
decreased in samples treated with RSV at 5 and 22 hours after 
sulforaphane treatment and increased in sample treated with 
sulforaphane before infection in comparison to infected control 
without treatment. 
The second set of samples, corresponding to western blot in Figure 
3.12 was also analysed by PCR. Results are shown in Figure 3.14.  
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Figure 3.14. Percentage RSV expression in comparison to L32 in 
BEAS-2B cells treated with sulforaphane corresponding to western 
blot in Figure 3.14. 
 
Percentage increase of RSV in comparison to housekeeping gene (L32) in BEAS-2B cells treated with 
5nM of sulforaphane pre and post infection for various amount of time, ranging from 1hr to 22hours. 
 
Control sample is negative for virus. There is an increase in the 
amount of virus with sulforaphane treatment in almost all samples in 
comparison to non-treated infected sample. Results from 
experiments conducted do not follow a pattern and are difficult to 
explain in any other way than error while conducting the experiment 
or analysing samples. 
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Experiment was modified and additional control samples with 
Dimethyl Sulfoxide (DMSO) were added to see whether this reagent 
used to dissolve sulforaphane has influenced results. DMSO is a 
commercial solvent, used in experiments as a carrier of sulforaphane 
due to its cell permeability- the ability to cross cell membrane and 
allow sulforaphane to enter the cell. Experiment with 3 additional 
conditions was conducted- cells treated with DMSO at -1hour, 22 
hours and 46 hours. The first two samples were collected at 24 hours 
and the last one at 48 hours. Results of PCR performed on samples 
from this experiment are shown in Figure 3.15. 
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Figure 3.15. Percentage RSV expression in comparison to L32 in 
BEAS-2B cells treated with sulforaphane and DMSO.  
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Results show decrease in RSV in samples treated with DMSO and 
increase in those treated with sulforaphane in comparison to control 
sample.  
As no pattern of results emerged, It was decided to take a step back 
and design a simpler experiment, which could demonstrate 
relationship between the reagents on a basic level. New experiment 
consisted of only three conditions:  cells were infected with RSV and 
treated with Sulforaphane or DMSO. Results are shown in Figure 
3.16. 
Figure 3.16. Expression of RSV in BEAS-2B cells treated with 
sulforaphane and DMSO. 
 
Changes in the amount of RSV detected by PCR in BEAS-2B cells treated with sulforaphane or DMSO. 
Each condition in duplicate. Outliers were excluded 
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3.17 Expression of RSV in BEAS-2B cells treated with sulforaphane 
and DMSO after calculating the average from duplicates. 
 
Changes in the amount of RSV detected by PCR in BEAS-2B cells treated with sulforaphane or DMSO. 
Values from duplicates of each conditions were averaged after excluding outliers.  
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Table 2. Table presenting data exported from the PCR spreadsheet 
after analysis, corresponding to PCR results from Figure 3. 16. 
 Sample Name Detector Ct Ct (duplicate) 
1 RSV1 PPIA 21.7051 21.5946 
1 RSV2 PPIA 20.0895 20.1206 
1 RSV3 PPIA 35.2495 36.0177 
1 RSV+sulf1 PPIA 21.92 21.9835 
1 RSV+sulf2 PPIA 32.408 32.8241 
1 RSV+Sulf3 PPIA 20.3151 20.4382 
1 RSV+DMSO1 PPIA 28.7124 28.6368 
1 RSV+DMSO2 PPIA 21.5269 21.6592 
1 RSV+DMSO3 PPIA 29.6093 29.7256 
1 RSV1 RSV A2 21.5776 21.6884 
1 RSV2 RSV A2  20.3287 20.4059 
1 RSV3 RSV A2 32.2829 33.4199 
1 RSV+sulf1 RSV A2  22.3861 22.2982 
1 RSV+sulf2 RSV A2  33.45 33.5543 
1 RSV+Sulf3 RSV A2 20.6452 20.7361 
1 RSV+DMSO1 RSV A2  28.6407 28.5598 
1 RSV+DMSO2 RSV A2  22.0635 21.9107 
1 RSV+DMSO3 RSV A2  29.9743 29.7656 
The amount of RSV in cells was calculated as follows:  
1. Average Ct value for each sample and each probe was calculated from duplicates. 
2. The average ct value for the house keeping gene L32 minus the average ct value for RSV.  
3. 2 to the power of n, where n = value determined in step 2.  
4. 100 divided by n, where n= the value calculated in step 3.  
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Statistical analysis of the results showed that difference between 
RSV and RSV with DMSO samples is not statistically significant with 
a two-tailed P value of 0.93. The mean of RSV minus RSV and 
DMSO equals 0.02 with a 95% confidence interval from -0.72 to 0.75. 
Difference between RSV and RSV with Sulforaphane samples is not 
statistically significant either with two-tailed P value of 0.2. the mean 
of RSV minus RSV Sulf equals 0.27 with 95% confidence interval 
from -0.34 to 0.88. Data from t-tests is presented in Table 3. 
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Table 3. Unpaired t-test data. 
a) RSV and RSV+DMSO comparison 
 Group   RSV     RSVDMSO   
Mean 0.92 0.91 
SD 0.13 0.21 
SEM 0.10 0.15 
N 2    2 
P value and statistical significance:  The two-tailed P value equals 0.2. By conventional criteria, this 
difference is considered to be not statistically significant.  
Confidence interval: The mean of RSV minus RSVDMSO equals 0.27 
95% confidence interval of this difference: From -0.34 to 0.88 
Intermediate values used in calculations:  t = 1.9, df = 2, standard error of difference = 0.14 
b) RSV and RSV+SULF comparison 
Group   RSV     RSV sulf   
Mean 0.92 0.65 
SD 0.13 0.16 
SEM 0.01 0.11 
N 2              2         
 
P value and statistical significance: The two-tailed P value equals 0.2.  By conventional criteria, this 
difference is considered to be not statistically significant.  
Confidence interval: The mean of RSV minus RSV sulf equals 0.27 
 95% confidence interval of this difference: From -0.34 to 0.88 
Intermediate values used in calculations:  t = 1.9,  df = 2, standard error of difference = 0.14 
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3.3. Discussion 
The first step in optimisation of experiment was finding the right 
antibody. True molecular weight of Nrf2 has been causing a lot of 
controversy since its discovery over a decade ago.  Very 
comprehensive report by Lau et al stresses the recent raise of 
interest in Nrf2 in various research environments.Error! Bookmark 
not defined. However, it also explains that a large portion of research 
projects, report the apparent wrong molecular weight of Nrf2 due to 
confusion about the migratory pattern of the molecule. This review 
provides evidence that the predicted molecular weight of Nrf2 is ~95-
110 kDa not ~55-64 kDa based on its 2-kb open reading frame, 
which a large portion of available research projects report.  These 
authors present data based on chemical activation, vector driven 
mammalian expression and recombinant protein expression. This 
report and conversations with experienced colleagues conducting 
research involving Nrf2 helped with selecting the right antibody 
(Figure 3.1). Abcam antibody was the only one detecting ~100 kDa 
band. Looking at the blot, it becomes clear that there is a lot of other, 
non-specific bands detected by all antibodies. This is a common 
problem with Nrf2 western blots and makes this laboratory method 
technically challenging. The next step in experiment optimisation was 
finding the right cell line. Two different airway epithelial cell lines 
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were compared and results are shown in Figure 3.2. BEAS-2B cells 
show sulforaphane induced expression of Nrf2, A549 cells express 
Nrf2 continually despite change of experimental conditions. In order 
to be able to show Nrf2 induction by sulforaphane, BEAS-2B was the 
cell line of choice for all experiments involving Nrf2 and sulforaphane, 
which is consistent with literature.133 Optimal concentration of 
sulforaphane was examined in a dose response experiment 
presented in Figure 3.3. The strongest expression of Nrf2 was seen 
in samples treated with 2 and 5 nM of sulforaphane. Five nM was 
chosen as the optimal concentration of sulforaphane for further 
experiments, as it has also been previously reported in successful 
induction of Nrf2134. The final step of optimisation was choosing the 
most efficient time of Nrf2 induction by sulforaphane. Time courses 
were conducted on both infected and non-infected cells to see 
whether time for optimal induction changes with infection. Results of 
a time course experiment on non-infected cells are included in Figure 
3.4. and on both infected and non-infected in Figure 3.5. and show 
the strongest expression of Nrf2 at 1 and 4 hours. Because of 
possible inconsistency of densitometry results discussed in Section 
4.3, the time chosen for maximal induction for future experiments 
was 4 hours, as it’s been previously reported in literature.135 
 116 
 
Interesting observation from this blot, is that the amount of Nrf2 does 
not necessary increase in RSV infection, which has previously been 
reported in literature.136 Antibody also detected two bands which is 
surprising and might be explained by the use of different percentage 
gel for this particular blot. Experiment was modified and additional 
time of sulforaphane stimulation was added before viral infection. It 
might have been the case, that there is a difference in Nrf2 
expression, depending on whether cells were exposed to 
sulforaphane before infection.  Results are presented in figure 3.6. 
and show that Nrf2 expression is stimulated by sulforaphane. The 
highest induction was achieved with treatment for two hours (at 22 
hours time point) and this time point was added to some of the later 
experiments as it is likely to show changes. However, the most 
important observation for this experiment is that Nrf2 is induced in all 
samples with different treatment times which creates good starting 
point for further experiments, as Nrf2 could be key for affecting RSV 
replication at any of these time points. 
It is important to note that results from blots 3.4, 3.5. and 3.6. are 
inconsistent and it is difficult to see a pattern emerging. 
After optimisation and gaining all necessary information to conduct 
the experiment, sulforaphane was added to samples for four hours 
prior to viral infection and cells were harvested at 24 hours, excluding 
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controls harvested at 0 hours. Flow diagram of the experiment is 
presented in Figure 3.7 and results in Figure 3.8. Cells have been 
successfully infected with virus and there is no contamination of 
controls. Signal of Nrf2 band is stronger in sample with added 
sulforaphane which confirms Nrf2 induction. There is no change in 
RSV protein expression between samples with and without 
sulforaphane treatment which is a crucial finding for the hypothesis 
and indicates that these results do not support the idea that RSV 
expression is influenced by sulforaphane. Nrf2 band disappears in 
samples infected with RSV. This could mean that RSV down-
regulates Nrf2 expression.  It could be a case of virus infection 
leading to transcription factor degradation and not Nrf2 inhibiting 
replication of virus in a cell as previously thought. There is not much 
information available about the effect of RSV infection on Nrf2 
expression, however, a paper by Komaravelli et al. published in 
January 2015, after we concluded Nrf2 experiments, states that Nrf2 
undergoes deacetylation-proteasomal degradation in RSV infection 
which supports our findings.137  
Experiment was repeated to see if similar results are obtained or if a 
pattern emerges. Results are shown in Figure 3.9. Nrf2 band gives 
stronger signal in non-infected samples treated with sulforaphane 
which confirms Nrf2 induction. Signal is weaker in infected sample 
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without treatment like in the previous blot which could support the 
idea of Nrf2 degradation by RSV. Densitometry was performed on 
this blot and confirmed results. Figure 3.10. shows results of 
repeated experiment but these results differ from the ones obtained 
before. There is no Nrf2 induction by sulforaphane and the amount of 
Nrf2 does not decrease with infection like previously. Samples do not 
show changes apart from increase in Nrf2 in control sample 
harvested at 24 hours (not treated and not infected). This result is 
unexpected and no pattern emerged which might be explained by an 
error while conducting the experiment or analysing the results and 
highlights the need to repeat the experiment. To examine if induced 
sulforaphane affected RSV protein expression, samples from 
experiment with induction of Nrf2 before and after infection was 
analysed on western blot with anti-RSV antibody.  
Results shown in figure 3.11 confirm successful infection of samples 
and lack of contamination of control. The polyclonal antibody detects 
multiple bands which correspond to RSV proteins of the following 
molecular weights: Protein G-90kDa, Protein F- 55 kDa, Protein N- 
46kDa, Protein P- 35kDa, Protein M- 28 kDa and M2-1 22kDa.138 
Unfortunately, there is no difference in the amount of RSV protein 
between samples, which is not what we were hoping to see 
according to our main hypothesis. This experiment was repeated 
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adding two more control samples. Results, presented in figure 3.12. 
do not show a difference between samples apart from the last one 
(treated with sulforaphane for 2 hours and harvested 48 hours post 
infection) where the band is weaker. This however, could be caused 
by uneven protein loading as there is no loading control for blots in 
Figures 3.11 and 3.12 due to technical problems with anti-actin 
antibody at the time. This is also why densitometry could not have 
been carried out, however, the lack of change in RSV expression 
between samples is indicated by western blot. The decrease in 
protein amount in the last sample can also possibly be explained by 
sulforaphane being cytotoxic after this amount of time as it has been 
previously reported to cause reduced cell viability.139 This however, is 
only a speculation and experiments should be conducted once again 
with actin control and densitometry to see if that change is 
reproducible. 
Western blot analysis of samples did not support the hypothesis that 
RSV expression changes with Nrf2 induction, however, this method 
only looks at proteins in samples. To see whether the hypothesis can 
be supported using a different laboratory method, samples were 
analysed by PCR, which is a technique quantifying viral RNA 
expression. It could have been the case that RNA was present in the 
sample but the protein not. Plaque assay would have been the best 
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method for looking at viable virus however this technique is also the 
most difficult one. This could be the next step in this project, once 
more laboratory experience is obtained. 
First set of samples analysed with PCR (Figure 3.13) correlates to 
western blot in Figure 3.11. Negative control confirms no 
contamination and successful infection of other samples. Results 
show decreased signal of RSV in samples treated with sulforaphane 
at 5 and 22 hours and increase in sample treated with sulforaphane 
before viral infection. Even though decrease in RSV with 
sulforaphane treatment is what we wanted to achieve, increase in the 
sample treated prior to infection is surprising and difficult to explain 
which makes the set of results less reliable due to possible error. In 
order to see if results are reproducible or whether there is a pattern 
emerging, the second set of samples from western blot 3.12 was also 
analysed by PCR (Figure 3.14). Results show successful infection 
and lack of contamination of controls but again increase in viral RNA 
in almost all samples is difficult to interpret and any differences  can 
most probably be explained by intra-experimental variation while 
either conducting experiment or analysing samples. 
Experiment was modified and additional control samples with DMSO 
were added. It was suspected that DMSO, which is a carrier of 
sulforaphane, could influence results (Figure 3.16). There is 
 121 
 
decrease in RSV in samples treated with DMSO and increase in 
those treated with sulforaphane.  Increase in RSV is inversely 
proportional to the length of exposure to sulforaphane. This could 
suggest that the amount of RSV increasing with time in samples 
treated with sulforaphane could be the virus replicating in cells and 
sulforaphane having no effect on it. It was decided to take a step 
back and design a simpler experiment which could demonstrate 
relationship between reagents used in the experiment in a more 
straight forward manner.  Results of this experiment are shown in 
Figure 3.16 and 3.17. Figure 3.16 presents values from duplicates 
and figure 3.17 averaged values. Statistical analysis with a non-
paired t-test revealed that results are not statistically significant. 
Overall, Nrf2 induction probably does not influence RSV expression 
as majority of western blots for RSV and RSV PCR did not show 
change, however, it is also obvious that there was a lot of technical 
difficulties due to lack of previous laboratory and research 
experience and other technical problems. If it was not for time 
limitation of the degree, experiments should be conducted once 
again with loading controls and densitometry. Bigger N number 
created by repeating experiments would enable statistical analysis of 
quantifiable results. DMSO influence on results should be further 
examined by creating more experimental conditions with this reagent. 
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Experiments based on plaque assay should be conducted once more 
laboratory experience is gained. Another alternative experimental 
approach could be looking at different viral RNA, as only one gene 
was checked for during PCR analysis. As Nrf2 is known to change 
cellular location in infection,140 immunofluorescence could bring 
interesting results, especially if all: nucleus, Nrf2 and RSV are 
labelled with different colours. 
An idea that emerged from a portion of results was that RSV might 
have a destructive effect on Nrf2 (Figure 3.9). This is a potential for 
further experiments, especially that Nrf2 has been reported to be 
degraded by RSV by a different research group141 but because this 
result was not reproduced in more experiments and at the time there 
was no literature available about this interaction, it was decided to 
conclude the Nrf2 study at this point. 
 
 
 
 
 
 
 123 
 
4. Changes in the ubiquitination of proteins during RSV 
infection 
 4.1 Introduction: 
Proteomics is the study of the proteome, a set of proteins produced 
and modified by an organism or cell which determine its structure 
and function. 142 Mass spectrometry, a proteomics related technology 
can be used to provide information about the structure and function 
of a large number of proteins expressed in one sample.  By 
analysing samples taken under different conditions proteomics, using 
mass spectrometry, allows insight into how protein expression  
changes under a given set of experimental conditions.143 Data used 
as the starting point for this project was generated by Dr Angela 
Fonceca, Dr Brian Flanagan and Dr Paul McNamara working with 
Prof Rob Beynon and Dr Debra Simpson from the Liverpool 
proteomics group. Their experiments defined the changes in the level 
of ubiquitination of proteins following RSV infection and identified 62 
differentially ubiquitinated proteins when comparing uninfected and 
RSV infected A549 airway epithelial cells. Six of those proteins 
(described in Section 1.4.4.) were selected for further validation and 
study. These six proteins were selected because their level of 
ubiquitination either increased or decreased and showed the greatest 
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level of change following RSV infection (DDX21) or because they 
were known to be involved in interferon signalling after viral infection 
(MAVS).  
In the experiments we used MG132 which is a specific, cell 
permeable, reversible and potent proteasome inhibitor.144 If a protein 
is ubiquitinated and broken down by the proteasome, we would 
expect the amount of the ubiquitinated form to increase following 
MG132 treatment. Determining which proteins change their level of 
poly-ubiquitination following the infection could help identify new 
biochemical pathways involved in the host defence or viral 
replication, and new targets for potential therapeutic intervention. 
Table 4. presents proteomics data involving six proteins of interest 
chosen for this project. 
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Table 4. Proteomics data including 6 proteins of interest used in the 
experiment during the project. 
Name of the 
protein 
Molecular 
Weight (kDa) 
Heavy/Light 
chain ratio 
Light/Heavy 
chain ratio 
More/Less of 
ubiquitinated form in 
infected cells 
Prohibitin 29.8 0.657 1.52 More 
Ribosomal 
Protein S10 
18.9 1.508 0.66 Less 
MAVS 40.4 0.418 2.39 More 
DDX21 87.3 0.477 2.10 More 
HMGB1 24.9 2.036 0.49 Less 
Annexin A1 0.49 1.96 0.49 Less 
 
Table presents data from the proteomics experiments on 6 proteins studied further in this project 
(Prohibitin, RPS10, MAVS, DDX21, HMGB1, Annexin A1). Heavy chain represents non-infected cells 
which have been labelled with a stable isotope Carbon13 by growing them in C13 supplemented media, 
whereas light chain- the infected ones grown in standard C12 supplemented media. Heavy over light 
chain ratio, or light over heavy is the crucial data point. It is expressed in both ways in the table. If ratio 
is below 1 for light over heavy chain, it means more of the protein was ubiquitinated in non-infected 
cells. If value is over 1, more of the protein is ubiquitinated in light fraction (infected cells). Samples 
were harvested at 4 hours post infection. Table also includes molecular weight of each protein. 
 
These experiments aim to show if, following viral infection, host 
proteins may be differentially ubiquitinated either as part of the hosts 
cells defence response to infection or as a result of viral induced 
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changes in cellular metabolism. These differences in ubiquitination 
level could lead to an increase or decrease in protein breakdown or 
turnover via the proteasome (Ubiquitin Proteasome System 
explained in Section 1.4.3.) either as part of host cell defence or viral 
manipulation of normal cellular processes to favour its reproduction.  
The hypothesis examined was that viral infection of airway epithelial 
cells leads to changes in ubiquitination of normal cellular proteins. 
These changes represent either RSV, manipulation of normal cellular 
proteins to support replication or host cell defence to infection.  
This was examined firstly by treating infected and non-infected cells 
with MG132 to inhibit proteasome activity and examining if protein 
expression changed.  Secondly, differential ubiquitination was also 
examined using immunoprecipitation with either antibodies against 
individual proteins to purify them followed by western blotting with 
antibody against ubiquitin to determine how much of this fraction was 
ubiquitinated. Alternatively, immunoprecipitation with anti-ubiquitin 
followed by western blot with a protein specific antibody to determine 
how much of specific protein was to be found within the ubiquitin 
fraction. Thirdly, as differential ubiquitination can lead to a change in 
cellular localisation, immunofluorescence was used to examine 
protein localisation in both infected and non-infected cells.  
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Potentially differentiated molecules studied in this project include 
DDX21, an RNA helicase, a member of the DexD/H-box helicases 
family. All RNA helicases, are highly conserved enzymes which 
change secondary RNA structures and ribonucleoprotein complexes 
by the use of ATP energy during RNA metabolism.   Even though the 
exact mechanism of this process is not known, DDX21 is essential in 
pre-rRNA processing.  It has been shown that DDX21 plays a major 
part in regulating transcriptional and post transcriptional steps of 
ribosome biogenesis, and has a crucial part in coordinating 
transcriptional programs across different nuclear compartments.  
DDX21 has been proposed as a host restriction factor which modifies 
expression of the influenza A gene by down regulating viral RNA 
formation, and as a result viral protein production at early stages of 
infection.   No further information about interaction of DDX21 with 
virus has been published. 
Another protein MAVS is an intermediary protein, essential in the 
interferon signalling pathways triggered by viral infection as it 
activates transcription factors responsible for regulation of IFN-β 
signalling and plays a role in anti viral immunity.  There are a number 
of transcript variants encoding different isoforms of the gene. 
Diseases associated with MAVS include viral infections such as 
Hepatitis C and Influenza A.   Its peroxisomal and mitochondrial 
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forms, act simultaneously to create antiviral states in a cell. During 
infection with a virus, peroxisomal MAVS initiates IFN-independent 
production of defence factors which protect cells in the short-term. 
The mitochondrial type of MAVS initiates IFN-dependent signalling 
pathway with delayed kinetics. This in turn intensifies and stabilises 
the defense against a virus. It has been suggested that MAVS is 
likely to protect cells from apoptosis  and that Lys-48-linked 
polyubiquitination of MAVS leads to its proteasomal degradation.  
HMGB1 is a DNA binding protein associated with chromatin, 
composed of 215 aminoacids and of a molecular weight of 24 kDa.  It 
plays a significant role in inflammation. Macrophages and monocytes 
secrete HMGB1 which acts as a as a cytokine like mediator. It has 
been reported to promote viral growth and enhance viral polymerase 
activity.145  It undergoes ubiquitination at Lys12, 43, 50, 112, 114, 
128 and 157.  The role of HMGB1 in the host response to respiratory 
viral infection has not been further studied.  
Annexin A1, also known as lipocortin1, has been identified as an 
important therapeutic target in treatment of inflammation with 
glucocorticoids due to its inhibitory effect on phospholipase A2. Their 
main mechanism of action is through increasing the synthesis and 
function of Annexin A1, which downregulates phospholipase A2 
blocking eicosanoid production and suppressing a number of 
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leukocyte inflammatory events (Epithelial adhesion, emigration, 
chemotaxis, phagocytosis).  These processes lead not only to 
suppression of the immune system, but also to two main products of 
inflammation- prostaglandins and leukotrienes. It undergoes 
ubiquitination at Lys58, 166, 274.  It has been suggested that 
Annexin negatively regulates viral RNA replication but its role in viral 
infections has not been studied in depth.146 
Ribosomal protein S10 (RPS10) is involved in several cellular 
pathways, one of which include viral RNA transcription and 
replication and ctivation of the mRNA reported in Influenza A 
infection. The knowledge about this process is however fragmentary. 
RPS10 undergoes ubiquitination at Lys38, 47, 59, 107, 138, 139.  
Prohibitin encoded by the PHB gene is involved in negative 
regulation of transcription from RNA polymerase II promoter.  
Prohibitin undergoes ubiquitination at Lys128.  The influence of 
prohibitin on controlled viral replication has not been previously 
studied. 
4.2. Results 
The aim of this series of experiments was to firstly validate the 
suggested changes in ubiquitination observed in the proteomics and 
to determine if these potentially key proteins which control cell’s 
 130 
 
response to RSV or allow viral replication, change in their level of 
expression or ubiquitination after RSV infection and proteasome 
inhibition. 
4.2.1. Changes in protein expression in A549 cells after RSV 
infection and proteasome inhibition.  
Firstly, samples were run on a blot probed with anti-ubiquitin 
antibody. It was to determine if there are ubiquitinated proteins in 
samples and whether the amount of these changes with RSV 
infection and proteasome inhibition.  
4.2.1.1. Influence of RSV infection on the expression of ubiquitin in 
A549 bronchial epithelial cells with and without proteasome 
inhibition. 
A549 cells were infected with RSV at three different concentrations 
and after two hours treated with MG132 for another two hours. 
Results of a western blot with samples probed with FK2 anti-ubiquitin 
antibody are shown in Figure 4.1. 
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Figure 4.1. Level of ubiquitin in A549 cells infected with increasing 
concentrations of RSV and treated with proteasome inhibitor 
(MG132). 
 
Western blot analysis showing changes in the amount of ubiquitinated proteins in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 3 different concentrations of virus (MOI= 
1:4; 1:1; 4:1). After 2 hours, 4 samples were treated with 10mM of MG132 in DMSO for another 2 hours. 
Protein ubiquitination was analysed with species independent, mono- and polyubiquitinated conjugates 
monoclonal Anti-FK2 antibody agains ubiquitin (Enzo). Actin band of 42 kDa provided loading control.  
 
Antibody detects correct seized, high molecular weight, smeared 
band reported in other research studies, consistent with detection of 
multiple ubiquitinated proteins. Detected ubiquitin bands are 
enhanced in samples treated with MG132 consistent with inhibition of 
the proteasome. No differences were observed between samples 
treated with different MOIs of virus and the level of ubiquitin in each 
sample. There is also no overall visible difference in the total amount 
of ubiquitinated proteins between infected and non-infected samples 
whether treated with MG132 or not. However, some proteins could 
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be more and some less ubiquitinated, as individual changes in 
protein ubiquitination will not be evident. 
It was decided that the most optimal concentration of virus to further 
examine changes in Ubiquitination would be 1:1 ratio of virus particle 
to cell.  
4.2.1.2 Influence of RSV infection on the expression of Nrf2 in 
bronchial epithelial cells with proteasome inhibition. 
As Nrf2 is known to be ubiquitinated and broken down by the 
proteasome during RSV infection147, it was decided to look at this 
molecule first in order to validate the experimental approach and 
show that MG132 inhibition was working in the experiments. Results 
are shown in Figure 4.2 
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Figure 4.2. Level of Nrf2 in A549 cells infected with RSV and treated 
with proteasome inhibitor (MG132). 
 
Western blot analysis showing changes in the amount of Nrf2 in A549 cells after RSV infection and 
proteasome inhibition. Cells were infected with one concentration of virus (MOI 1:1). After two hours, 
two samples were treated with 10mM of MG132 in DMSO for another two hours. The expression of Nrf2 
was analysed with rabbit monoclonal Anti-Nrf2 abcam (ab62353) antibody. Aactin band of  42 kDa 
provided a loading control. Molecular weight of the detected Nrf2 is ~ 95/105 kDa. 
 
Densitometric analysis of this western blot bands intensities was performed using Li-cor Imgae Studio 
Lite Versio 3.1. software. Nrf2 bands were normalised to loading control actin band and are presented 
in the graph above.  Samples were infected with 1:1 MOI of RSV and treated with MG132 for 2 hours. 
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Western blot analysis of this experiment detects two bands for Nrf2. 
Both bands are in range of ~95-110 kDa which is the correct 
molecular weight reported in other research studies.148 Top band in 
the RSV infected and MG132 treated sample is darker even though 
the protein loading is lower. No change between the control sample 
and the infected sample is apparent. As expected, densitometry 
results show increase in Nrf2 in MG132 treated samples in 
comparison to control and increase in Nrf2 in infected sample treated 
with MG132 in comparison to non-infected one. 
 
4.2.1.3. RSV influence on the expression of DDX21 in bronchial 
epithelial cells with proteasome inhibition. 
The Hep2 cell line expresses DDX21constituitivly and can be used 
as a positive control.149 Detection of DDX21 in Hep2 cells, would 
suggest that our reagents are working and that the experiment has 
been carried out correctly. Figure 4.3 shows western blot analysis of 
samples which were infected with RSV, treated with MG132 after 2 
hours and harvested at 4 hours.  
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Figure 4.3. Level of DDX21 in A549 cells infected with RSV and 
treated with proteasome inhibitor. 
 
Western blot analysis showing changes in the amount of DDX21 in A549 cells after RSV infection and 
proteasome inhibition. Cells were infected with one concentration of virus (MOI 1:1). After 2 hours, 2 
samples were treated with 10mM of MG132 in DMSO for another 2 hours and harvested 4 hours post 
infection. Expression of DDx21 was analysed with rabbit monoclonal anti-DDX21 abcam (ab182156) 
antibody. No loading control is available for this blot. Desired molecular weight detected by antibody is 
80/87 kDa. 
The result shows a strong band of high molecular weight in Hep2 
cells and lighter bands in A549 cells.  For A549 cells there is a 
difference in the pattern of bands between samples. Additional band 
of lower molecular weight appears in A549 samples without MG132. 
This band is darker in the infected sample. Samples treated with 
MG132 show enhanced signal and bands have different higher 
molecular weight pattern. In comparison to control, there is more of 
the heavier form of DDX21 in infected sample without proteasome 
inhibition. To examine the possibility that the lower molecular weight 
bands seen in both control and infected sample could be breakdown 
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product of DDX21, experiment was repeated with samples harvested 
at 4 and 24 hours. Results are shown in Figure 4.4. 
 
Figure 4.4. Level of DDX21 in A549 cells infected with RSV and 
treated with proteasome inhibitor, harvested at 4 and 24 hours. 
 
Western blot analysis showing changes in the amount of DDX21 in A549 cells after RSV infection and 
proteasome inhibition. Cells were infected with one concentration of virus (MOI 1:1). After 2 hours, 4 
samples were treated with 10mM of MG132 in DMSO. Two samples for 2 hours and harvested at 4 
hours and another to for 22 hours and harvested at 24 hours post infection. Expression of DDX21 was 
analysed with rabbit monoclonal anti-DDX21 abcam (ab182156) antibody. No loading control is 
available for this blot. Desired molecular weight detected by antibody is 80/87 kDa. 
 
Results are similar and consistent with western blot in Figure 4.3. 
The top band is enhanced in samples where proteasome was 
inhibited and there are multiple lower molecular weight bands in 
infected samples.  
To examine these changes further, design of the experiment was 
changed by introducing more controls which could explain different 
patterns of bands. Samples were infected with two concentrations of 
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virus to look for a dose response. Palivizumab, a monoclonal 
antibody used prophylactically for infants in the high risk group of 
RSV infection, was added to one of the samples to remove virus and 
determine if other molecules present in the RSV preparations could 
be influencing results. Two Hep2 lysates, one of which was treated 
with MG132, were added as positive controls. Results are shown in 
Figure 4.5. 
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Figure 4.5 Level of DDX21 in A549 cells infected with RSV and 
treated with proteasome inhibitor and palivizumab.  
 
Western blot analysis showing changes in the amount of DDX21 in Hep2 and A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with two concentrations of virus (MOI= 0,2:1; 
1:1). After 2 hours, 3 samples were treated with 10mM of MG132 in DMSO and one with palivizumab for 
another 2 hours and harvested 4 hours post infection. Expression of DDX21 was analysed with rabbit 
monoclonal anti-DDX21 abcam (ab182156) antibody. Actin  band of  42 kDa provided loading control. 
Desired molecular weight detected by antibody is 80/87 kDa. 
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Densitometric analysis of western blot band intensities was performed using Li-cor Imgae Studio Lite 
Versio 3.1. software. DDX21 band was normalised to loading control actin band and presented in the 
graph above. Axis x shows sample number: 1. Non- infected sample without treatment. (A549) 2. 
Sample infected with 0.2:1 MOI if virus without treatment. (A549)  3. Sample infected with 1:1 MOI of 
virus without treatment. (A549)  4. Non-infected sample with palivizumab treatment. (A549) 6. Non-
infected sample with MG132 treatment. (A549) 7. Infected sample with MG132 treatment. (A549) 7. 
Non-infected sample without treatment. (Hep2) 8. Non-infected sample with MG132 treatment (Hep2). 
Axis y shows the amount of protein in each sample. 
Antibody detects a band of ~87 kDa in all samples. In A549 cells 
there are additional bands of lower molecular weight. Bands in 
control sample give stronger signal than in infected samples. Change 
between the rest of the samples is not apparent. Densitometry 
results confirm higher level of DDX21 in control sample and no 
difference between the other samples. These results show a different 
pattern from that observed in previous blots with no other apparent 
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differences due to RSV or MG132. It is possible that there is a 
problem with this result which will be further discussed in Section 4.3. 
4.2.1.4. Influence of RSV infection on the expression of Ribosomal 
Protein S10 (RPS10) in bronchial epithelial cells with and without  
proteasome inhibition. 
A549 cells were infected with 3 different concentrations of RSV (cell: 
virus particle ratio of 4:1, 1:1, 1:4) and treated with 10mM of MG132 
for 2 hours. Cell were then harvested at 4 hours and used for 
western blots and immunohistology. 
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Figure 4.6. Level of RPS10 in A549 cells infected with increasing 
concentrations of RSV and treated with proteasome inhibitor 
(MG132). 
 
Western blot analysis showing changes in the amount of RPS10 in A549 cells after RSV infection and 
proteasome inhibition. Cells were infected with three different concentrations of virus (MOI 1:4,1:1,4:1). 
After 2 hours, 4 samples were treated with 10mM of MG132 in DMSO for another 2 hours. Expression 
of RPS10 was analysed with rabbit monoclonal Anti-RPS10 abcam (ab151550) antibody. Anti-actin  
band of provided loading control. Molecular weight of detected RPS10 is 19kDa. 
 
Densitometric analysis of western blot band intensities was performed using Li-cor Imgae Studio Lite 
Versio 3.1. software. RPS10 band was normalised to loading control actin band and presented in the 
graph above. Axis x shows sample number: Cells were infected with various MOIs of RSV and treated 
with MG132 for two hours. 
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As expected, a band of 19 kDa consistent with RPS10 was 
observed. Enhanced intensity of RPS10 band is apparent in samples 
treated with MG132. Relation between the amount of virus added to 
sample and the amount of RSP10 detected is proportional. In 
samples infected with virus but without MG132 treatment RPS10 
levels were almost undetected. Densitometry confirms higher levels 
of RPS10 in MG132 treated samples, increasing proportionally to the 
amount of virus added to cells. The amount of RPS10 also 
decreases in proportional manner to the amount of RSV added to 
samples without MG132 treatment. The biggest difference is 
observed in MG132 treated sample, infected with 4:1 MOI of virus. 
The rest of studied proteins showed similar results to RPS10, namely 
successful proteasome inhibition with MG132 but no change with 
viral infection. 
4.2.2. Changes in the expression of proteins in A549 cells after RSV 
infection and proteasome inhibition, analysis by immunoprecipitation. 
In the following set of experiments, antibody against ubiquitin (anti-
Ub) was used for detection of proteins ubiquitination. Each protein of 
interest was also detected by corresponding antibody. 
Immunoprecipitation of samples aimed to show whether changes 
seen on blots without immunoprecipitation are related to 
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ubiquitination and whether the amount of ubiquitinated proteins 
changes with RSV infection. This technique enabled examination of 
two properties of one protein at the same time. In this case, 
identifying the right protein and whether it is ubiquitinated or not. To 
achieve this, magnetic beads were coated with anti-ubiquitin 
antibody, which allowed ‘pulling’ all ubiquitinated proteins from the 
samples. Samples were then loaded onto gel and blot probed with 
antibody against the protein of interest or the other way round. This 
should reveal all ubiquitinated proteins in samples. 
4.2.2.1. RSV influence on the expression of ubiquitin in bronchial 
epithelial cells subjected to immunoprecipitation. 
Magnetic beads were coated with anti-ubiquitin antibody to 
precipitate ubiquitinated proteins from sample and then presented on 
a blot probed with the same antibody. 
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Figure 4.7. RSV influence on the expression of ubiquitinated proteins 
in A459 cells infected with RSV and treated with MG132.  
a) cell lysates without immunoprecipitation, western blot probed with 
anti-ubiquitin antibody. 
b) cell lysates after immunoprecipitation with anti-ubiquitin antibody, 
western blot probed with the same antibody. 
 
Western blot analysis showing changes in the amount of ubiquitinated proteins in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 1:1 MOI of RSV. After 2 hours one sample 
was treated with 10mM of MG132 in DMSO for another two hours.  
a) Cell lysates were analysed with species independent, mono- and polyubiquitinylated conjugates 
monoclonal anti-FK2 antibody against ubiquitin. 
b) Cell lysates were subjected to immunoprecipitation with species independent, mono- and 
polyubiquitinylated conjugates monoclonal Anti-FK2 antibody against ubiquitin. Protein ubiquitination 
was then analysed with the same antibody.  
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Antibody detects the correct, smeared band of high molecular weight 
which has previously been reported in other studies and is consistent 
with that shown in figure 4.1. Ubiquitin band shows enhanced 
intensity in MG132 treated samples. Difference between infected and 
non-infected samples is not apparent. 
 
Experiment was repeated, adding one experimental condition and 
MG132 infected treated sample. Results are shown in figure 4.8. 
 
Figure 4.8. RSV influence on the expression of ubiquitinated protein 
in A459 cells infected with RSV and treated with MG132 after 
immunoprecipitation with anti-ubiquitin antibody. Western blot probed 
with anti-ubiquitin antibody. 
 
Western blot analysis showing changes in the amount of ubiquitinated proteins in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 1:1 MOI of RSV. After two hours two 
samples were treated with 10 mM of MG132 in DMSO for another two hours. Cell lysates were 
subjected to immunoprecipitation with species independent, mono- and polyubiquitinylated conjugates 
monoclonal Anti-FK2 antibody. Protein ubiquitination was analysed with the same antibody.  
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Antibody detects a band consistent with ubiquitin, which is darker in 
non-infected, MG132 treated sample. There is also additional band 
at the level of 50 kDa in all samples- possibly heavy chain of the 
Immunoglbulin used during immunoprecipitation.  
 
4.2.2.2. Influence of RSV infection on expression of DDX21 in 
bronchial epithelial cells subjected to immunoprecipitation. 
In the next blot, magnetic beads were coated with anti-DDX21 
antibody and blot probed with anti-ubiquitin antibody. Results are 
shown in Figure 4.9 
 
Ubiquitin band gives the strongest signal in non-infected sample 
treated with MG132. There are also two bands detected at the level 
of 25 and 50 kDa in all samples consistent with immunoglobulin light 
and heavy chains respectively. (See Figure 4.9) 
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Figure 4.9. RSV influence on the expression of ubiquitinated DDX21 
in A459 cells with proteasome inhibition after immunoprecipitation 
with anti- DDX21 antibody. Cell lysates immunoprecipitated with anti- 
DDX21 antibody. Western blot probed with anti-ubiquitin antibody. 
 
Western blot analysis showing changes in the amount of ubiquitinated DDX21 in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 1:1 MOI of RSV. After 2 hours, 2 samples 
were treated with 10mM of MG132 in DMSO for another 2 hours. Cell lysates were subjected to 
immunoprecipitation with rabbit monoclonal anti-DDX21 abcam (ab182156) antibody. Protein 
ubiquitination was analysed with species independent, mono- and polyubiquitinylated conjugates 
monoclonal Anti-FK2 antibody against ubiquitin. 
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Figure 4.10. RSV influence on the expression of ubiquitinated 
DDX21 in A459 cells with proteasome inhibition after 
immunoprecipitation with anti-ubiquitin antibody. 
a) cell lysates without immunoprecipitation, western blot probed with 
anti-DDX21 antibody. 
b) cell lysates after immunoprecipitation with anti-ubiquitin antibody, 
western blot probed with anti- DDX21 antibody. 
 
 
Western blot analysis showing changes in the amount of ubiquitinated DDX21 in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 1:1 MOI of RSV. After 2 hours, 1 sample 
was treated with 10mM of MG132 in DMSO for another 2 hours.  
a) Cell lysates were analysed with rabbit monoclonal anti-DDX21 abcam (ab182156) antibody. 
b)Cell lysates were subjected to immunoprecipitation with species independent, mono- and 
polyubiquitinylated conjugates monoclonal Anti-FK2 antibody against ubiquitin. Protein ubiquitination 
was then analysed with rabbit monoclonal anti-DDX21 abcam (ab182156) antibody.  
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Results obtained from this experiment resemble the first DDX21 blot 
(Figure 4.3). Distribution of bands changes between samples and 
lower molecular weight bands disappear with MG132 treatment. In 
immunoprecipitated samples, the strongest signal is detected in 
infected sample without MG132 treatment. The 50 kDa band is again 
detected in all samples. 
These results led to the next step, to make sure that samples were 
infected with RSV and that there was no contamination of control. In 
order to prove it, western blot analysis of the same samples was 
carried out using anti-RSV antibody. Results are shown in Figure 
4.11 
 
Polyclonal RSV antibody detects 3 bands possibly corresponding to 
3 RSV proteins. Protein G ~90 kDa, protein F~55 kDa and protein 
N~46 kDa. 90 kDa band and a lighter bands ~40kDa is detected only 
in infected samples. 46kDa band is detected in all samples.  
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Figure 4.11. RSV expression  in A459 cells infected with RSV and 
treated with MG132. 
 
Western blot analysis showing changes in the amount and pattern of bands of RSV  in A549 cells after 
RSV infection and proteasome inhibition. The cells were infected with 1:1 MOI of RSV. After 2 hours, 
one sample was treated with 10mM of MG132 in DMSO for another 2 hours. Cell lysates were analysed 
with purified IgG conjugated to Biotin anti-RSV antibody(7950-0004Bio-rad). 
 
4.2.2.3. RSV influence on the expression of RPS10 in bronchial 
epithelial cells subjected to immunoprecipitation. 
RPS 10 was immunoprecipitated from samples. Western blot was 
probed with anti-ubiquitin antibody to demonstrates changes in 
ubiquitinated RSP 10 in the samples. Results are shown in Figure 
4.12. 
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Figure 4.12. RSV influence on the expression of ubiquitinated RPS10 
in A459 cells with proteasome inhibition. 
a) Cell lysates without immunoprecipitation, western blot probed 
with anti-ubiquitin antibody. 
b) cells lysates immunoprecipitation with anti-RPS10 antibody, 
western blot probed with anti-ubiquitin antibody. 
 
Western blot analysis showing changes in the amount of ubiquitinated RPS10 in A549 cells after RSV 
infection and proteasome inhibition. Cells were infected with 1:1 MOI of RSV. After 2 hours, 2 samples 
were treated with 10mM of MG132 in DMSO for another 2 hours.  
a) Cell lysates were analysed with species independent, mono- and polyubiquitinylated conjugates 
monoclonal Anti-FK2 antibody against ubiquitin. 
b)Cell lysates were subjected to immunoprecipitation with rrabbit monoclonal anti-RPS10 abcam 
(ab151550) antibody. Protein ubiquitination was analysed with species independent, mono- and 
polyubiquitinylated conjugates monoclonal anti-FK2 antibody against ubiquitin. 
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Results of both sets of data show stronger signal in MG132 treated 
samples. There is no change between infected and non-infected 
samples.  
It the next western blot analysis, the samples were 
immunoprecipitated with RPS10 antibody and then probed with the 
same antibody.  
Results show a similar pattern to previous blots. RPS10 band is 
enhanced in samples treated with MG132. Signal detected in 
infected sample is weaker than in the non-infected one. 
The other proteins examined similarly did not show any change with 
viral infection. 
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4.3. Discussion 
The main objective of the work described in this chapter was to 
determine whether following infection there is a difference in 
ubiquitination of proteins selected from the proteomics (DDX21, 
annexin A1, HMGB1, RPS10, prohibitin and MAVS). The first step 
was to assess whether there are ubiquitinated proteins in the 
samples and if so, whether their amount changes following viral 
infection or proteasome inhibition. To examine this, cells were 
infected with increasing amounts of RSV and treated with MG132. 
Samples were then analysed by western blot with anti-ubiquitin 
antibody. The molecular weight of ubiquitin is 8,5 kDa. Results in 
Figure 4.1 show, instead of a single band at that level, a series of 
high molecular weight bands which look like a smear. This can be 
explained by ubiquitin attaching to proteins and creating a chain, 
making their molecular weight significantly higher. Bands are 
enhanced in MG132 treated samples indicating that the proteasome 
was inhibited successfully and caused accumulation of proteins, 
normally destroyed by this organelle. There is no change between 
samples infected with various MOIs of virus and level of ubiquitin. It 
is also not possible to tell the difference in the total amount of 
ubiquitinated proteins on the blot, as we see a cumulative effect. As 
proteomics data suggests, some proteins are more and some less 
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ubiquitinated, some are up- and some down-regulated. In order to 
determine changes in ubiquitination of each particular proteins and 
the optimal MOI of the virus, samples were analysed by western blot 
technique with antibody against each target protein. In order to 
validate the experimental approach and show further that 
proteasome inhibition was working, the first molecule probed for was 
Nrf2, as it was known to be ubiquitinated and degraded by 
proteasome. (Section 1.3.1). 
Results of this blot (Figure 4.2.) show two bands detected for Nrf2, 
both in the correct range of ~95-105 kDa. Top band is darker in 
MG132 treated samples which suggests successful inhibition of 
proteasome, and validates this experimental approach. A possible 
explanation of the results is that lighter band is non-
ubiquitinated/mono-ubiquitinated form of Nrf2 and heavier band 
polyubiquitinated one, as only polyubiquitinated Nrf2 is degraded by 
proteasome. Due to uneven loading of proteins between those 
samples visible on actin loading control, densitometry was 
performed. There is no difference between infected and non-infected 
samples without MG132 treatment. However, when comparing 
between MG132 treated samples, there is more of the heavier form 
in infected sample which could show that under viral infection Keap1-
Cul3 ubiquitination system is disrupted and leads to accumulation of 
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Nrf2 in a cell. A link between MG132 treatment and increased Nrf2 
level has been reported before.150 
The first protein from the proteomics analysed by western blot was 
DDX21. (Figure 4.3) Results show a very thick band in Hep2 cell 
lysates, used as a positive control for DDX21 expression, in 
comparison to A549 cell lysates. This thick band could be a result of 
discrepancy in protein loading between samples as Hep2 cell lysate 
was prepared separately to A549 lysates. Unfortunately, there is no 
loading control available for this blot which makes it impossible to 
perform control normalised densitometry. Interesting finding on this 
blot is that pattern of DDX21 bands varies between samples. The 
band of interest (~87 kDa) is enhanced in MG132 treated samples 
which indicates proteasome inhibition. This band is also darker in the 
infected sample in comparison to non-infected one. Due to lack of 
densitometry results, it is impossible to quantify this result and 
compare to proteomics value. There are additional lower molecular 
weight bands in infected samples without MG132 treatment, these 
could be breakdown products from RSV generated degradation of 
DDX21. This however is only a speculation as, it has only been 
suggested that DDX21 is degraded by another respiratory virus- 
Influenza A virus.151 An additional, heavier band was detected in 
samples treated with MG132 which could be explained as 
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accumulation of the polyubiquitinated form of DDX21 normally 
destroyed by proteasome. 
Results from a repeated experiment with additional samples 
harvested at 24 hours posit infection (Figure 4.4.) are consistent and 
strongly suggest that DDX21 is normally broken down via the 
proteosome in A549 cells both with and without RSV. In both infected 
samples, lower molecular weight bands appear again which supports 
the theory that RSV infection leads to DDX21 degradation. However, 
it has to be pointed out that this experiment alone cannot definitively 
confirm that it is the virus having a degrading effect on the cell, as 
there is still the possibility that it is the cell not producing or reducing 
amount of DDX21 whilst infected.  
In an attempt to explain the appearance of extra bands and their 
pattern, this experiment was modified and extra controls were added. 
One of the samples was treated with palivizumab, a monoclonal 
antibody used prophylactically for infants in high risk group of RSV 
bronchiolitis, in order to see if it is the virus or other contaminants in 
the viral preps that influence the results. Two Hep2 controls were 
added to see if MG132 has an effect on DDX21 in this cell line. This 
time, the amount of protein in samples was first measured by BCA 
assay (Section 2.3) to ensure an even loading of protein in all 
samples and loading control was provided in a form of actin 
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band(Figure 4.5). A band of ~87 kDa was detected in all samples 
which confirms role of Hep2 as positive control. In all A549 samples 
there are additional lower molecular weight bands present, which 
have the same pattern in all experimental conditions. There is no 
difference in the amount of protein between samples, apart from 
control sample (without infection or treatment), in which the signal is 
stronger. These findings are confirmed by densitometry. This blot 
only validates Hep2 cells as control for DDX21 expression but does 
not show change in expression of DDX21 between different 
conditions. It is hard to explain the lack of change between samples 
but it is most probably due to a human error while conducting the 
experiment or western blot analysis. This points to a need for more 
repeats of experiments as the control with palivizumab could be very 
informative. The antibody could not be used in all experiments due to 
cost and limited availability. 
Infected and non-infected cells were analysed using 
immunohistology to determine whether cellular location of DDX21 
changes with infection.(Figure 4.5.). In healthy cells DDX21 is visible 
as green spherical shapes, contained within what are most probably  
nucleoli of the cell which is consistent with literature.152 To confirm 
this dual staining with a nucleolar protein would have to be 
performed. In infected cells, DDX21 is more dispersed and its colour 
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less intense. On closer observation, it could be interpreted that 
DDX21 escapes the nucleolus and migrates into nucleoplasm during 
infection. Together with results of western blots this could contribute 
to the possible explanation that DDX21 is degraded during viral 
infection, either by viral proteins or the cells own degradative 
mechanisms. It has been previously reported that in Influenza A 
virus, DDX21 is counteracted by the viral NS1 Protein.151 
Immunohistology results have a descriptive rather than quantifiable 
character, which makes it difficult to assess whether the amount of 
protein actually changes in different conditions.  The next step would 
be to quantify these results but a suitable method has not been found 
so far and results remain preliminary. Further research would have to 
be carried out to quantify these results. Potentially, samples could be 
analysed with immunochemistry where the chromogen intensity can 
be measured. Chromogen stains appear more intense in fields with 
more protein, unlike immunofluorescence, in which the brightness of 
a region is directly proportional to the amount of detected protein.153 
Because it is known that DDX21 inhibits Influenza virus transcription, 
the next useful addition to immunohistology would be staining with 
red fluorescent-labelled RSV to visualise change in virus location and  
determine if any RSV proteins co-localise with DDX21. 
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The same set of samples was next analysed with anti-RPS10 
antibody (Figure 4.7). Obvious accumulation of protein in samples 
treated with MG132 again indicates successful proteasome 
inhibition. The more RSV was added to the sample, the less protein 
there was in samples without MG132 treatment. Reverse relation is 
apparent in samples with MG132 treatment. The higher the MOI of 
virus, the more protein is present in the sample because the 
proteasome which would normally degrade it is inhibited. 
Immunohistology slides for RPS10 show the protein contained within 
multiple, small spherical shapes (most probably ribosomes) in 
cytoplasm of healthy cells. In infected cells, the protein is almost 
invisible. This correlates with western blot, and densitometry findings 
which might mean that the protein is down-regulated in RSV 
infection. RPS10 has been suggested to be involved in viral RNA 
transcription and replication and results of western blot and 
immunohistology analysis presented in this thesis, show the potential 
for an important interaction between this protein and RSV. This could 
be direct for example by NS1 or 2, or indirect through viral proteins 
acting on other cellular proteins which influence RPS10 expression 
and ribosome integrity. It is only an assumption that RSV is inflicting 
these changes directly and would have to be demonstrated in an 
additional way, perhaps by co-precipitation. Similarly to Nrf2 and 
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DDX21, it would be useful to incubate immunohistology slides with a 
PE stained anti-RSV antibody to show RSV proteins in red and its 
location in cells with and without infection. This result gives a reason 
for running more experiments with immunoprecipitation, to see 
whether it undergoes differential ubiquitination. 
The next stage of experiments was immunoprecipitation. For each of 
the proteins, optimal MOI was chosen on the basis of results from 
previous blots (Figure 4.1). Immunoprecipitation aimed to show 
whether changes on the blots are caused by protein ubiquitination 
and whether they can be linked to virus infection.  
The aim of the first two blots was to validate experimental approach 
and precipitate ubiquitin/ubiquitinated proteins from samples. Figures 
4.7 and 4.8 show successful proteasome inhibition and ubiquitin 
precipitation from samples. A difference between infected and non-
infected cells is not apparent on the first blot. On the second one, the 
amount of ubiquitinated proteins is higher in non-infected samples 
treated with MG132 in comparison to infected cells with treatment. 
This could mean that overall the amount of ubiquitinated proteins 
decreases in RSV infection because of different ratios of 
ubiquitination for each protein but some would get up and some 
down regulated. More probably however, this could just be loading 
differences. This led to the next step which was immunoprecipitation 
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of target proteins one by one. A finding worth mentioning is an 
additional band at the level of ~55 kDa in all samples. Most probably 
it is immunoglobulin band which appears on further 
immunoprecipitation blots and is a common problem in 
immunoprecipitated samples in western blotting. It results from using 
antibodies raised in the same species for immunoprecipitation and 
western blotting which shows up as heavy and light chain on the 
level of ~25 and ~55 kDa on the image. Further optimisation of the 
experiment, such as antibody crosslinking, should be performed in 
future experiments in order to avoid this problem. 
 
Figure 4.9 shows samples immunoprecipitated with anti- DDX21 
antibody and probed with antiubiquitin antibody which should result 
in detection of ubiquitinated DDX21. Surprisingly, there is more 
ubiquitinated DDX21 in non-infected MG132 treated sample than in 
the one with RSV. This result is contrary to what was expected on 
the basis of proteomics data, however, the ~50 kDa immunoglobulin 
band which appears on this blot is also more enhanced in this 
sample. This could mean that protein loading is uneven and darker 
band in the non-infected MG132 treated sample simply means higher 
concentration of protein in this sample. The next, very important step 
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in optimising these experiments would be to find a way to provide 
loading control for immunoprecipitated samples. 
Figure 4.10 shows result of immunoprecipitation performed the other 
way round. Lysates were immunoprecipitated with anti-ubiqtuitin 
antibody and blot probed with antibody against DDX21. 
Retrospectively it would be very helpful if the blot consisted of the 
same samples as previously, not only 3 samples which is another 
suggestion for improvement in future experiment. Lower molecular 
weight bands appear in infected sample again (like in Figure 4.3.) 
which support the potential explanation of DDX21 being degraded by 
the virus. Pattern of bands in control samples is slightly different than 
in Figure 4.3. which makes the results for this protein inconsistent. In 
order to examine if difference in results is caused by an error during 
conducting the experiment such as contamination of controls with 
virus or unsuccessful infection of the RSV samples, anti- RSV was 
used on the samples. Results from Figure 4.11 show 3 bands 
detected for virus. These should correspond to three surface protein 
of RSV ~90 kDa protein G, ~55kDa protein F and ~46kDa protein N. 
Two of the bands on the blot match proposed molecular weights 
(Protein G and F) and are present only in infected samples. Third 
band present in all samples is most likely to be a non-specific band. 
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This blot would have to be repeated to see if the same pattern of 
bands appears again. 
The same approach was used for RPS10. Samples 
immunoprecipitated with anti-RPS10 antibody and probed with anti-
ubiquitin antibody in Figure 4.12, show successful inhibition of 
proteasome by accumulation of ubiquitinated RPS10 in samples 
treated with MG132. There is no difference between infected and 
non-infect samples. Again, in this case densitometry could give a 
more detailed, quantifiable results if there was a way of producing 
loading control. Lack of change on the blot led to the next step which 
aimed to validate that proteins are truly being precipitated from 
samples. To prove this, samples were precipitated with antibody 
against RPS10 and the same antibody used for western blot. This 
time infected, MG132 treated sample showed less RPS10 than non-
infected control. This data correlates to the proteomics data but to 
draw conclusions and preferably quantify it, a loading control would 
have to be produced and densitometric analysis conducted. It would 
also be helpful to turn the experiment around, like it was done with 
DDX21 and precipitate samples with anti-ubiquitin antibody and then 
analyse on a western blot with anti-RPS10 antibody. 
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5. Final discussion: 
In this study I have investigated the significance of Nrf2 signaling and 
ubiquitination of proteins in RSV infection. 
The first part of the project aimed to determine whether sulforaphane 
might reduce RSV replication in airway epithelial cells. As outlined in 
the introduction, sulforaphane or related compounds are found in 
foodstuffs and may form a potential therapeutic approach.  
Optimising experiment which aimed to answer the question, created 
smaller specific objectives which had to be achieved in order for the 
main experiment to be reliable. All these objectives including finding 
the correct antibody for detecting Nrf2, identifying appropriate cell 
line, concentration of sulforaphane and time of treatment were met. 
Majority of experiments have also proven that sulforaphane induces 
expression of Nrf2 in BEAS-2B bronchial epithelial cells, which is in 
agreement with available literature.154 However, there was no 
change in RSV protein expression between samples with and without 
sulforaphane treatment which is a crucial finding for the study and 
indicates that these results do not support the idea that RSV 
expression is influenced by sulforaphane. Results of many of these 
experiments were not consistent and often did not follow a pattern 
which partly can be blamed on technical difficulties due to lack of 
previous laboratory experience and temporary problems with 
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reagents but mainly means that it is likely that the hypothesis was 
wrong. Data generated during this research does not support the role 
in vitro for Nrf2 in suppressing viral replication in epithelial cells. Viral 
replication was measured by western blot and real time PCR for the 
N gene mRNA. It would be helpful to look at different analysing 
techniques like plaque assay to further confirm that functional viral 
levels are not reduced. This is one of the suggestions for future work. 
One of the potential reason why my experiments do not show the 
changespreviously reported, could be that, in vivo experiments using 
an animal model may give different results because the antiviral 
activity of other cells such as macrophages or neutrophils may be 
affected by NRF2 knockdown.155 In my  experiments I have only 
looked at in vitro conditions using the BEAS 2B human bronchial 
epithelial cell line.   
Results of Nrf2 experiments suggest a new idea, that Nrf2 might be 
degraded by virus. (Figure 3.9.) Decrease or complete removal of 
Nrf2 from samples infected with virus suggest that RSV could inhibit 
Nrf2 expression or have a degrading effect on it. This however, is 
only a hypothesis and would have to be further examined, however, 
Komaravelli et al study141 has recently confirmed that RSV infection 
down-regulates antioxidant enzyme expression by triggering 
deacetylation-proteasomal degradation of Nrf2.156 Similar result has 
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been reported in a different research group, which states that Nrf2 
expression was reduced in RSV infection as a potential mechanism 
for reducing gene expression of AOE.157 Even though our hypothesis 
has not been proved, this finding could still help in developing 
therapeutic agents against RSV or explaining why currently an 
effective treatment does not exist.  
The aim of the second part of the study was to validate data from a 
series of proteomics experiements and show if selected proteins 
change their level of expression or are differentially ubiquitinated 
following RSV infection. This could allow the identification of novel 
protein targets for development of new  therapuetics. Some of the 
proteins, such as prohibitin, Annexin A1, RPS10, HMGB1or MAVS 
did not show any change between samples in the experiments. 
DDX21 has been described as virus recognition protein in Influenza 
studies and as an essential component of ribosomes biogenesis.151 
Virus might be trying to degrade the protein in order to stop it from 
down regulating viral RNA and be more successful in early stages of 
infection process and also disable cell recognition mechanism so that 
viral RNA cannot be detected. 
Almost all experiments confirmed inhibition of the proteasome and if 
the project did not have to be concluded due to approaching deadline 
of the degree and more immunoprecipitation experiments were 
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conducted, majority of proteins shows high potential of proving that 
they are differentially ubiquitinated in RSV infection. The aims 
therefore have been met partially. The knowledge about proteins 
chosen for this study is fragmentary and some of the post-
translational modifications such as ubiquitination have not been 
studied at all. 
This research is the first one to show evidence that DDX21 could 
undergo ubiquitination and gives a basis for designing experiments 
which could prove this process. Western blots also suggest that 
DDX21 is degraded by RSV which has previously been reported for 
Influenza A but not for RSV. 
 5.1. Limitations 
The main limitation of this project was the restricted time to conduct 
experiments. More time would allow repeating each of the 
experiments at least 3 times to be able to assess if results are 
reproducible and if any patterns are emerging. It would also allow for 
the results to be quantified and statistical analysis to be conducted to 
see whether the change in results is statistically significant.  
Due to the lack of previous laboratory experience, many of 
conducted experiments, especially at the beginning of the year 
contained errors. Considering the large variety of laboratory 
techniques including cell culture, virus preparation, BCA assay, 
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western blots, PCR and immunofluorescence used during 12 months 
of this project, these mistakes were treated as a part of learning 
experience and were unavoidable.  Another consequence of no prior 
lab exposure is the lack of loading control as well as poor quality of 
some of the blots which made interpreting and quantifying results 
very challenging and incomparable. Technical difficulties which 
slowed down conducting experiments but could not have been 
avoided included issues like contamination of samples with 
mycoplasma for one of the immunofluorescence staining attempts. 
Each of the laboratory techniques used during this project has its 
own limitations, however, some of them proved to be especially 
challenging eg. use of western blotting for detecting Nrf2. Even 
though the methodology has been described many times in other 
research, optimisation of my experiments consumed a lot of time and 
many technical problems have been encountered on the way, such 
as antibody not detecting desired bands or detecting multiple non-
specific bands. The issue of differences in reporting Nrf2 molecular 
weight has been thorough described in Lau et al report and 
discussed previously in Section 3.3. The discrepancy between 
presented results in appearance of bands has been cause by use of 
different percentage gels in western blot. On lower percentage gel 
(12%) Nrf2 band is „separated” and appears as double band 
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whereas on higher percentage gel (15%) it looks like antibody 
detects only one band. In the future, all experiments involving the 
same molecule should be conducted using exactly the same 
reagents so that results are comparable. 
Densitometry is another technique which often appeared to be 
inconsistent with corresponding western blot like in Figure 4.9. This 
highlights the pitfalls of technique and why sometimes it is difficult to 
make western blot results quantifiable. Most of western blots have 
imperfections, eg one side of the blot has a higher background than 
the other or there are scratches on the blot which are picked up by 
the software on top of target protein bands. Densitometry is a way of 
confirming what can be seen on the blot with a naked eye but on 
worse quality blots results can be skewed because of the 
background noise.  
The main limitation to the PCR assay used in this project, is that it 
only measures N gene expression and as such is not able to detect 
any change in expression of other viral RNA or protein molecules. It 
might be the case that the change would have been detected for a 
different viral RNA.  
It is also important to note here, that any affect seen in the results 
could be directly done by RSV or indirectly by the cell responding to 
virus. It is an assumption that it is RSV that is causing these changes 
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and to be confident that they are truly caused by virus they need to 
be demonstrated by other techniques eg co-precipitation. 
Another limitation is the fact that all experiments were conducted in 
vitro and in order to confirm results interaction between molecules 
and virus should be studied in vivo.  It is possible that in a living 
organisms other factors would influence examined processes. 
The experiments show that DDX21 is degraded in response to RSV 
infection. As DDX21 is involved in ribosome assembly at the 
nucleolus, degradation of this molecule would almost certainly affect 
the structure and function of ribosomes, changing the ability of the 
cell to make proteins. It is not clear if this is a response of a host cell 
to viral infection which might in turn limit translation of viral mRNA to 
protein and virus replication, or alternatively the virus causing 
breakdown of DDX21 as part of its programme to manipulate the 
cell’s production of protein to favour viral replication. This could be 
tested at least in part by overexpressing DDX21 within the cell and 
seeing how this influences viral replication. In the respect to viral 
Influenza it is known that early in infection DDX21 limits viral RNA 
expression as part of the cell’s defence to viral infection.158 It remains 
possible that this is also the case in RSV infection but as DDX21 is 
degraded it seems more likely that RSV itself is causing a breakdown 
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of DDX21. It might be useful to use siRNA to reduce DDX21 
expression and determine how this influences RSV replication.  
 
5.3. Future work 
All experiments which showed evidence of changes should be 
repeated at least 3 times in order to prove that results are 
reproducible and allow statistical analysis. It would be also beneficial 
to add more time points and controls to the experiments eg. Samples 
treated with Palivizumab. A reliable method of quantifying western 
blots and immunohistology should be found and used for statistical 
analysis. 
All proteins of interest which showed changes in expression following 
viral infection should be studied by immunofluorescence including 
triple color staining for nucleus, target protein and RSV to examine 
interactions between proteins and virus and determine whether 
infection influences protein expression and localisation in a cell. 
Results also show that MAVS and DDX21 could potentially be 
degraded by RSV in infected cells. Although we cannot take the 
initial results alone, they are promising and should be further 
examined by more western blots and other laboratory techniques. 
Seeing these differences suggests that these proteins have a role in 
either defending cell from infection or in viral replication within the 
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cell. As MAVS is essential in IFN pathway due to its role in activating 
IFN 1 signaling production it would be beneficial for virus to degrade 
it and stop its production of interferon which is one of the main ways 
the cell protects itself against the virus. Inhibiting MAVS would be 
important at multiple stages of viral infection as it has been shown 
that the molecule initiates production of defence factors which 
protects the cell in short term as well as stabilizes the defense 
against the virus with delayed kinetics159. 
The fact that, this research is the first one which could have 
suggested ubiquitination of DDX21 and its degradation by RSV is 
very promising and should be further examined. It also validates the 
approach of proteomics as a method of identifying proteins which 
change in ubiquitination after RSV infection, at least in A549 cells. 
Another suggestion for future work could be more experiments with 
immunoprecipitation reactions to prove it is differentially and gene 
complementation studies.  
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